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In the lead optimisation of drug candidates, the first discovery pharmacokinetic (PK) 
in vivo study is of great importance to provide an initial assessment of the drug PK 
parameters. Data from in vivo PK studies is generally used to give feedback to 
chemists to improve the properties of the lead compound series, and also to calculate 
the initial doses in further effect studies. As the throughput in lead optimisation in 
drug discovery is constantly increasing, methods for high throughput bioanalysis and 
sample reduction are of great interest. This study presents an evaluation and a method 
for cassette analysis (compounds incubated separately followed by combining each 
time point for multiple compounds) of discovery drug compounds from PK in vivo 
studies in rat using high performance liquid chromatography/ mass spectrometry 
(HPLC-MS/MS) and ultra performance liquid chromatography/ mass spectrometry 
(UPLC-MS/MS) for quantification. Strategies for sample reduction, fast 
chromatography and challenges in ionization suppression using different formulation 
solutions are addressed. 
The number of DMPK (drug metabolism and pharmacokinetics) studies in the drug 
industry has increased vastly over the last years. Only at AstraZeneca R&D 
Södertälje, the number of PK studies performed has increased more than threefold the 
last five years. Therefore, the need to develop time saving methods has also increased. 
It is of great interest to the drug industry to reduce sample analysis time, increase 
throughput and maintain data quality by using methods, which are reproducible and 
easily implemented. 
Liquid chromatography/ mass spectrometry (LC-MS/MS) is widely used for 
quantitative analysis. This is usually a time- and resource-consuming process. The 
need to rapidly identify lead compounds requires as short intervals between the 
sample submission and the data reporting as possible. 
Cassette analysis decrease the number of samples to analyze, and therefore reduces 
the time for analysis compared to the traditional discrete methods. But there can be 
limitations. A pooled analysis may result in a low limit of quantification (LOQ) 
and/or limitations in data parameters obtained. The LOQ can be a problem because of 
the dilution of the samples in the cassette analysis. But because of the more sensitive 
mass spectrometers that have been developed the recent years, this is of less concern 
than earlier. 
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In the present study, a cassette analysis method was developed and evaluated. The 
method should be able to analyze samples from three in vivo studies at once. Six drug 
compounds were chosen as reference compounds. Two cassette groups (n = 3) were 
established, containing basic and acidic reference compounds respectively. 
The compounds were analysed on different LC-MS/MS systems, and for all analytes, 
MS/MS methods and chromatography methods were developed. Further, there were 
made standard curves with different experiments. Spiked plasma simulating the PK 
profile of the reference compounds and samples from in vivo animal studies at 
AstraZeneca were used for the assessment. Equal volumes of three plasma samples 
corresponding to each time point of three individually dosed rats were pooled and 
further prepared with protein precipitation and analysed with HPLC-MS/MS or 
UPLC-MS/MS. The matrix effect of different formulations, in terms of ionization 
suppression was also examined. Finally a validation experiment was performed to be 
able to evaluate the previous results in the study. 
The results showed that there were no large differences between the discrete/single 
and cassette/pooled samples. However, the results showed some variations, and not all 
the samples fulfilled the acceptance criterion of ± 25 %. This difference is not related 
to the LC-technique, but rather to the variability in the analytical method and 
variations in the sample preparations. The basis for this assumption is verified by the 
validation experiment at the end of this study. 
The loss of sensitivity due to extra dilution in the sample preparation step is only of 
concern when working with very small concentrations. Some formulations can give 
ion suppression e.g. PEG 400 in this study. Therefore, when using PEG 400, an ion 
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Abbreviations and concepts 
ACN   Acetonitrile 
AZ   AstraZeneca 
CE   Collision energy 
CMC   Carboxymethylcellulose 
CV    Cone voltage 
DMA   Dimethyl acetamid 
DMPK    Drug metabolism and pharmacokinetics 
DMSO   Dimethylsulfoxide 
ESI   Electrospray ionization  
ESP+      Electrospray in positive ionization mode 
ESP-    Electrospray in negative ionization mode 
F   Flow rate 
GC   Gas chromatography 
HPMC   Hydroxypropyl methylcellulose 
HPLC    High-performance liquid chromatography   
Hz   Hertz (cycles per second) 
in vitro  Experiment performed in test tubes 
in vivo   Experiment performed in living organisms 
IS   Internal standard 
IV                                Intravenous dosing route 
LC   Liquid chromatography 
LC-MS/MS    Liquid chromatography-mass spectrometry/mass spectrometry 
Lipoid S100®  Phospholipid formulation used for drugs with poor water  
   solubility for parenteral application 
LOD                            Limit of detection 
LOQ   Limit of quantification 
M    Mol/litre 
MCC   Microcrystalline cellulose 
MeOH   Methanol 
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MRM   Multiple reaction monitoring 
MS     Mass spectrometry 
MS/MS   Mass spectrometry/mass spectrometry (Tandem mass           
   spectrometry) 
m/z   Mass to charge ratio 
N2   Nitrogen 
PEG                            Polyethylene glycol 
PO                               Oral dosing route 
Q    Quadrupole 
QC                              Quality control 
QuanLynx   Quantification data program of the software MassLynx 4.0 and  
   4.1 
QuanOptimize  Optimization data program of the software MassLynx 4.0 and 
   4.1 
R&D   Research and development 
S/N   Signal to noise ratio 
Tween80®  Polyoxyethylene sorbitanmonostearate 
UPLC                         Ultra Performance Liquid Chromatography 















Screeningfasen for oppdagelse av nye legemiddelkandidater i farmakokinetiske in 
vivo studier er et viktig steg for å anslå initielle farmakokinetiske (PK) parametre. 
Data fra disse studiene benyttes til optimering av PK parametre fra kjemiske serier, og 
for å kalkulere initielle doseringsverdier i videre in vivo studier. På grunn av den 
stadig økende mengden av data, og det medfølgende behovet for økt throughput i den 
analytiske metoden, er det et konstant behov for nye raskere metoder og for reduksjon 
av antall prøver som skal analyseres. Hensikten med denne studien var å utvikle og 
evaluere metoder for kassettanalyse/ pooling av prøver fra tre standardiserte PK in 
vivo studier. Strategier som ble undersøkt nærmere var steg i prøveopparbeidelsen, 
sensitivitet, ionesuppressjon/ enhancement, forskjeller mellom diskrete/single og 
kassett/poolede analyser og validering av resultater fra analysene. 
 
I denne studien ble det benyttet seks refransesubstanser. Substansene ble undersøkt 
hver for seg, og også i to kassettgrupper (n = 3) med henholdsvis kun basiske og kun 
sure forbindelser sammen. Warfarin ble benyttet som internstandard (IS) ettersom den 
lar seg detektere i både positiv og negativ mode. Referansesubstansene ble benyttet 
for å undersøke hvordan pooling av prøver påvirker nøyaktighet, presisjon, LOQ og 
PK-parametre. Blank plasma fra rotte ble tilsatt ulike mengder referansesubstanser 
(spiked plasma) for å lage standardkurver og simulerte PK profiler. Prøver fra in vivo 
dyrestudier ved AstraZeneca ble også undersøkt. Like volumer fra tre plasmaprøver 
med korresponderende tidspunkter i PK-kurvene fra individuelt doserte dyr ble poolet 
sammen. Matrix effekter på grunn av ulike doseringsformuleringer som for eksempel 
cyclodextrine eller PEG 400 ble også undersøkt med hensyn på ionesuppressjon. 
Både for å se på forskjeller mellom ulike analysesystem, og på grunn av 
kapasitetsproblemer ble prøvene analysert på ulike HPLC-MS systemer, og også på 
UPLC-MS. 
 
Resultatene fra denne studien viser at det ikke er store forskjeller mellom prøver som 
er analysert som diskret/singel eller som kassett/poolet. Ved å benytte kassettanalyse 
fremfor diskrete analyser øker throughput betraktelig. Man vil også spare analysetid 
og kostnader knyttet til dette. 
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Det finnes imidlertid enkelte variasjoner som avviker fra aksept kriteriene på ± 25%. 
Dette synes derimot ikke å skyldes ulikheter mellom diskret og kassett, men heller på 
grunn av variasjoner i analysemetode/ spredning innenfor analysesystem. Grunnlaget 
for denne antagelsen kommer frem i validering-/ spredningsforsøk som også viser noe 
variasjon. Dermed vil det kunne forekomme enkelte variasjoner uansett om man 
analyserer som diskret eller kassett. 
På grunn av ekstra fortynning i prøveopparbeidelsen ved kassettanalyse taper man litt 
sensitivitet, men dette har kun betydning ved svært lave konsentrasjoner. Enkelte 



























The common mission of major pharmaceutical companies such as AstraZeneca is to 
develop new efficient medicines to improve people’s health. DMPK screens at early 
stages in the development are important when potential new medicines are 
investigated. The increased speed with which scientists can profile new drug 
candidates will shorten the time needed to develop a new medicine. In order to 
implement these screens in shorter time periods, the use of higher throughput assays 
are based on different strategies and approaches such as fast chromatography, direct 
injection, parallel MS methods and various sample reduction methods where the 
cassette approach belongs. 
In the drug industry, DMPK studies are performed in order to obtain useful 
information on the properties of potential drug candidates. The number of these 
studies has increased vastly over the last years. 
DMPK studies can be divided into for steps: sample preparation, analysis, 
quantification and reporting. The analysis step is a limiting factor since it is relatively 
time consuming, and with the ever-increasing number of samples to analyze, this 
limitation will increase. 
On the other hand, the development of faster and more efficient mass spectrometers 
not only decreases the analyze time, but it also increases the quality and the quantity. 
The use of autosamplers, robot methods, double- and even triple column systems also 
provides faster analyze times. But in the drug industry there will always be a desire to 
perform more analyses in shorter time periods. Therefore, the opportunity to analyze 
samples from several studies at once, which the cassette mode gives, will be of great 
value in the future [5].  
 
 
1.1 Aim of the study 
The aim of this study was to develop and evaluate methods involving cassette analysis 
that would generate reliable results. The final objective was to develop a cassette 
method that could be used for analysis of biological samples from three different 




























2.1 Liquid Chromatography 
High-performance liquid chromatography (HPLC) is the most used method in 
determining and analysis of medicines in pharmaceutical and biological material. The 
method involves a liquid, the mobile phase that is compressed with a pump through an 
injector and a column filled with a material that gives high-resolution separations. The 
separations is taken up by a detector that gives an electronic response which is 
adapted by a computer system giving arise to a chromatogram. 
Liquid chromatography is a physical separation method that acts through selective 
distribution between a liquid and a solid phase. The solid-/stationary phase is based on 
silica with hydrophobic adsorbents bounded to silanol groups. The mechanism of 
separation is based on the difference between the analyte distribution in relation to the 
mobile and stationary phase. 
The column is together with the mobile phase, separating the compounds in the 
sample. An ideal column should separate the compounds in as short time as possible, 
and give as small diffusion as possible of the compounds when being transported by 
the mobile phase. 
There are several different detectors available for liquid chromatography. Some 
examples are the UV-detector, the fluorescence detector or the electrochemical 
detector. A mass spectrometer is widely used as a detector to provide both qualitative 
and quantitative information. 
In HPLC, there are a great number of variables like the columns particle size, the 
composition of the stationary phase and the mobile phase, the flow rate and the 
properties of the analytes that affects the separation [8,9]. 
 
2.2 Mass spectrometry 
 As a result of the ability to combine the mass spectrometer with other 
chromatographic techniques, such as liquid- and gas chromatography, the usage of 
mass spectrometry has increased vastly over the last years. A mass spectrometer is 
using the differences in the relationship between mass to charge to separate ions in 
gas phase. The information obtained from a mass spectrometer is used for both 
quantitative and qualitative analyses.  
The mass spectrometer instrument can be divided into four main regions. 
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Source region: the samples are introduced into the ionization source. Ions are 
generated from the molecules by inducing a loss or gain of charge. After ionization, 
the molecule ion usually has enough residual internal energy to break into fragments. 
 
Transfer region: the ions are transported through the radio frequency lens that delivers 
them in a tightly focused beam to the separator. 
 
Analyzer region: in the analyzer region, the ions are separated according to their 
mass/ charge ratio. 
 
Detector: at the detector, the signal is amplified and detected. A photomultiplier 
dynode is usually used as the detector. As the ions strike the dynode, an emission of 
electrons are resulting. The electrons then strike a phosphorus screen that releases 
photons that are detected by the photomultiplier [7,8,9]. 
 
2.2.1 Electrospray 
Electrospray ionisation (ESI) is a widely used ionisation technique when a mass 
spectrometer is used as a detector in HPLC. The sample is provided into the mass 
spectrometer fluid stream, which passes through a capillary tube. At the end of this 
capillary, there is a strong electric field, which enable the fluid to be transformed into 
small droplets. To the ion source, it is also added a hot nitrogen gas, causing the 
droplets to evaporate. Then the electric field increases, and the ions move towards the 
droplets surface. The mutual repulsion between like charges on this surface becomes 
so great that it exceeds the forces of the surface tension, causing the ions to leave the 
droplets through a cone into the mass analyzer [7,9].  
 
2.2.2 Tandem mass spectrometry (MS/MS) 
A tandem mass spectrometer consists of two mass separators (quadrupoles) and a 
collision cell. The mixture of ions from the ion source is separated by the first 
quadrupole (Q1) where a precursor (parent ion) is selected. The ion(s) of interest are 
then introduced to the collision cell (Q2), where they are exposed to a collision gas, 
causing them to break into fragments (daughter ions). The selected fragment(s) are 
then analysed in the following quadrupole (Q3) in order to obtain a daughter ion 
spectrum [7,8]. 
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2.2.3 Ultra Performance Liquid Chromatography (UPLC) 
The throughput and resolving power of liquid chromatography has increased 
considerably the past decades. The development of the UPLC system has been an 
important contribution to this evolution. Based on 1.7 and 1.8 µm particles and 
instrumentation, the system delivers increased levels of resolution speed and 
sensitivity. Because the column is packed with smaller particles, the instrumentation 
is capable of higher pressure operations, which have led to reduced system volumes, 
faster autosamplers and detectors with higher data capture rates. But, also –to obtain 
the benefits of smaller particles in the column, other measures need to be considered. 
Pumps capable of delivering solvent smoothly and reproducibly at the higher 
pressure, and the detector sampling rate must be high enough to capture enough data 
points across the peaks. It is also desirable with injection valves designed to work at 
higher pressure, fast injection cycles and narrow capillaries [8, 12]. 
 
2.3 Cassette analysis 
To increase speed and throughput when using HPLC-MS/MS systems, the major time 
saving strategies include sample reduction and cassette analysis. Figure 1 summarizes 
the strategies and approaches that have been employed for increasing the throughput 




Figure 1 High throughput technologies and strategies using HPLC-MS/MS [1] 
 
 
As shown in the figure, cassette dosing and cassette assay provides sample reduction, 
which gives higher throughput and speed, which will save time, instrumentation, and 
personnel and hence costs. 
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It is important to distinguish between the two approaches cassette dosing and cassette 
assay (cassette analysis). Cassette dosing involves dosing the test-animal with a 
mixture of multiple compounds, whereas cassette analysis involves pooling the 
different compounds together prior to the sample preparation and the analysis. In the 
present study, we will not go further into the cassette dosing approach, but concentrate 
on cassette analysis of in vivo pharmacokinetic studies. The cassette analysis approach 
is a widespread method in the drug industry, mainly to save time and costs, but is not 
widely used for in vivo studies. AstraZeneca R&D Södertälje has earlier not used 
cassette analysis for in vivo studies because of the number of issues to consider. Loss 
of sensitivity due to the pooling and hence diluting of the samples, which can involve 
higher limits of quantification (LOQ). There are also matrix effects, mainly ion 
suppression or ion enhancement that need to be considered. Pooling samples from 
different studies can involve several different formulation solutions in the same 
pooled sample. Endogenous compounds e.g. phospholipids can bias the analytical 
results, and of course the molecular weight of the analytes and their metabolites 
should not interfere with each other [1]. 
 
2.4 Matrix effects/ ion suppression 
An analytical sample consists of the analyte and the rest of the sample, which is the 
matrix. If the matrix affects the analyte and hence the analytical result in some way, 
there is a matrix effect. The mainly matrix effects to consider are ion suppression or 
ion enhancement. Matrix effects resulting in either ion suppression or ion 
enhancement of analyte response has become one of the most common cause of 
failure or errors in bioanalysis, and when not understood, it can lead to errors in the 
calculation of PK parameters in animal models. 
Matrix effects can cause stability issues for biological assays using LC-MS/MS. 
Major sources of matrix effects includes a few classes of endogenous phospholipids 
which are present in biological matrices such as plasma and serum.  
In a typical discovery PK study, drug candidates are administered to rats via the 
intravenous (IV) and/or the oral (PO) route. A solution formulation is required for the 
IV route, and is also preferable for the PO route in order to enhance absorption. 
Common formulation solutions are cyclodextrine, gluconic acid, meglumine and 
PEG. 
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To avoid interference between the phospholipids, the formulations and the analytes, 
the chromatography methods need to be modified such that the analytes of interest do 
not co-eluate with the regions displaying significant matrix effects. This can be done 
by optimizing the chromatographic conditions (e.g., using a longer HPLC gradient) to 




Selective and sensitive analytical methods for the quantitative evaluation of analytes 
are necessary for a successful conduct of pharmacology studies. Bioanalytical method 
validation includes procedures that demonstrate the usefulness of particular methods 
used for quantitative measurement of analytes in a given biological matrix, such as 
blood, plasma, serum or urine. Validation involves documenting, through the use of 
specific laboratory experiments, that the performances of the method are reliable for 
the analytical applications. 
It is necessary to perform a validation experiment to be able to evaluate other results 
in the study, to give evidence of adequate assay performance in the original lab/ 
method, and thus additionally prove reliability of data. 
A validation experiment can be performed by analysis of several samples at different 
concentration levels (quality controls, QC) over a specific time period. Acceptance 
criterions of percentage deviation, and how many samples that allow failing the 




































3. Methods and experimental 
3.1 Chemicals and solvents 
Warfarin was used as internal standard (IS) and supplied by compound management, 
AstraZeneca (Södertälje, Sweden). The reference compounds (diazepam, diclofenac, 
imipramine, naproxen, propranolol and rofecoxib) and the formulations 
(cyclodextrine, gluconic acid, meglumine, DMA, PEG 400, HPMC + Tween80® and  
MCC/NaCMC + Lipoid S100®) were also supplied by compound management 
AstraZeneca. Acetonitrile, methanol, acetic acid and ammonium acetate were 
purchased from E. Merck (Darmstadt, Germany). The Milli-Q water used for 
preparing solvents and solutions was obtained using a Reagent Grade Milli-Q Plus 
water purification system from Millipore Corporation (Bedford, USA). 
Dimethylsulfoxide (DMSO) was purchased from Sigma (St Louis, USA). Blank rat 
plasma was supplied from Animal Care, AstraZeneca R&D (Södertälje, Sweden). The 
rat plasma from the animal studies containing test compounds was supplied from 
DMPK, AstraZeneca R&D (Södertälje, Sweden). 
 
3.2 Apparatus 
The compounds were analysed on different LC-MS/MS systems, both because we 
wanted to evaluate the differences between systems, and because of capacity 
limitations. 
These systems were: 
 
 1. Quattro Ultima, 2-column system using H2O/ MeOH gradient 
 
 2. Quattro Ultima/Quattro Premier, 1 column system using H2O/ acetonitrile 
     gradient 
 
 3. Quattro Premier Acquity UPLC, 1 column system using H2O/ acetonitrile 
     gradient (Analysis performed both at AstraZeneca in Södertälje and at               










        
 
Figure 3 HPLC-MS/MS, CTC auto sampler, Rheos 2000 HPLC pump, Waters 
Quattro Premier XE 
 
 
The UPLC system (Figure 2) used a C-18 column, Acquity UPLC BEH C-18, 2.1x30 
mm with particle size 1.7µm, acetonitrile gradient, 2-80%, and flow rate 0.6 ml/min. 
The time between injections was approximately 1.6 minutes. 
 
The HPLC system (Figure 3) used a Hypurity C-18 column, 2.1x30 mm with particle 
size 5.0 µm, acetonitrile gradient, 2-80%, and flow rate 0.4 ml/min. The time between 
injections were approximately 3.5 minutes. When using the 2-column system with 
MeOH gradient 15-85%, the flow rate was 0.35 – 0.4 ml/min. The time between 
injections varied from 4 – 8 minutes. 
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3.3 Reference compounds 
 
                                        















Warfarin (IS), MW 308,34 
 










Figure 5 HPLC chromatograms, pooled compounds, 3.5 minutes between injections, 
1 column system, Hypurity C-18 column 
 
 
Compound Parent (m/z) Daughter (m/z) CV (V) CE (eV) Ion mode 
Diazepam 284.95 193.12 46 28 ES+ 
Imipramine 281.09 85.91 19 16 ES+ 
Propranolol 260.09 115.95 35 16 ES+ 
Warfarin (IS) 308.88 163.1 18 16 ES+ 
            
Diclofenac 293.85 250.1 19 12 ES- 
Naproxen 229.11 169.1 19 34 ES- 
Rofecoxib 312.97 284.94 37 22 ES- 
Warfarin (IS) 306.91 161.02 18 20 ES- 
Table 3.3-1 MS methods/ MRM-Scan transitions for the reference compounds 
 
All compounds were dissolved in DMSO, and had a concentration of 10 mM (stock 
solutions). 
 
3.4 Formulation solutions 
Dosing formulations are commonly used in pharmacokinetic (PK) studies during the 
early drug discovery stage. Examples of widely used formulations are cyclodextrine, 
gluconic acid, meglumine, methylcellulose, Tween 80 and polyethylene glycol (PEG). 
These formulations are dosed to test animals like rats together with other compounds, 
usually one or more drug candidates. The dosing vehicles are usually dosed through 
the intravenous (IV) or the oral (PO) route. A dosing formulation is required for the 
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IV route, and is also preferable for the PO route in order to enhance the absorption by 
dissolving the test compounds/ drug candidates.  
Like other compounds in the sample beside the analyte, the formulation can cause 
matrix effects. When pooling several in vivo compounds together, there can also be 
several different formulations in the same sample to analyze, causing further issues, 
especially concerning ion suppression or ion enhancement [4]. 
 
3.5 Phospholipids 
Major sources of matrix effects include a few classes of endogenous phospholipids 
and lysophospholipids that naturally occur in biological matrices such as plasma and 
serum. Phospholipid interference is a major component of matrix effect in bioanalysis. 
To reduce this matrix effect, it is necessary to account for the phospholipid impact on 
the analytes during the method development. Chromatography methods can then be 
modified such that the analytes of interest do not co-elute with regions displaying 
significant matrix effects from the phospholipids [10]. 
 
3.6 Pharmacokinetic profiles 
In this study, plasma samples were spiked with six drug compounds respectively 
where concentrations are corresponding to literature pharmacokinetic (PK) profiles.  
The PK concentrations of these compounds at eight time-points for the PO route are 











Table 3.6-1 Literature PK concentrations at eight time points for the oral route 
[15,16,17,18]* 
compound
0.25 0.5 0.75 1 1.5 2.5 6 24
Naproxen (µmol/L) 35 43 43 43 45 45 40 3
Diclofenac (µmol/L) 3 2 1.5 1 0.8 0.65 0.4 0.01
Rofecoxib (µmol/L) 0.07 0.15 0.27 0.3 0.45 0.6 0.45 0.07
Time (h)
compound
0.25 0.5 0.75 1 1.5 2.5 6 24
Imipramine (µmol/L) 0.36 0.27 0.43 0.27 0.27 0.23 0.15 0.07
Diazepam (µmol/L) 0.65 0.75 0.7 0.65 0.45 0.22 0.025 0.005
Propanolol (µmol/L) 0.28 0.16 0.1 0.06 0.04 0.02 0.008 0
Time (h)
 24 
*The literature PK (PO) values for Naproxen and Rofecoxib are taken from 
AstraZeneca in-house studies. 
 
The literature PK concentrations for the IV route are shown in table 3.6-2. The 
concentrations for the 24 hour time point for the compounds diclofenac, rofecoxib, 













Table 3.6-2 Literature PK concentrations at eight time points for the IV route 
[15,16,17,18]* 
 
*The literature PK (IV) values for Naproxen and Rofecoxib are taken from 
AstraZeneca in-house studies. 
 
3.7 LC-MS/MS analysis 
Before injection to the analysis system, either HPLC-MS/MS or UPLC-MS/MS, a 
sample preparation is necessary. In this step, preparation of requested concentrations 
are made, and proteins from the plasma are removed by protein precipitation. 
 
3.7.1 Preparation of stock solutions 
The reference compounds (diazepam, diclofenac, imipramine, naproxen, propranolol 
and rofecoxib) were weighed in separately from solid compounds to obtain a 
concentration of 10 mM of each compound when dissolved in DMSO. The stock 
solutions were stored in dark at room temperature. 
compound
0.03 0.1 0.3 0.6 1 3 6 24
Naproxen (µmol/L) 35 30 25 21 20 16 10 1
Diclofenac (µmol/L) 16 8 2.5 0.8 0.35 0.2 0.06
Rofecoxib (µmol/L) 5.50 4.40 2.80 1.00 0.50 0.08 0.04
Time (h)
compound
0.03 0.1 0.3 0.6 1 3 6 24
Imipramine (µmol/L) 2.2 2.1 2 1.9 1.7 1 0.5 0.01
Diazepam (µmol/L) 4.2 3.7 2.5 1.5 1 0.25 0.025
Propanolol (µmol/L) 10.5 8.5 6 4.5 3.5 1 0.25
Time (h)
 25 
3.7.2 Preparation of standards 
The stock solutions of the reference compounds had a concentration of 10 mM. 
Standard curves with eight points were produced from the standard stock solution by 
serial dilution, using ACN:H2O (50:50) as dilutor. The concentrations of the working 
standard solution were approximately: 50, 100, 338, 1125, 3750, 12 500, 33 333 and 
100 000 nM. The standards were diluted (1:10) with blank rat plasma in new tubes. 
From the plasma-diluted standards, 25 µL was transferred to a deep well plate. The 
concentrations received were: 5, 10, 34, 113, 375, 1250, 3333 and  
10 000 nM. The working standards were precipitated with a deproteinising solvent, 
150 µL ice cold ACN with 200 nM Warfarin.  The deep well plate was vortexed for 5 
minutes and centrifuged for 20 minutes, using 4000 rpm at a temperature of 4°C. 
After centrifugation, 120 µL of the supernatant was transferred to a new deep well 
plate, and 300 µL buffer (2 % ACN in 10 mM acetic acid) was added to the 
supernatant. The standards were injected on the LC-MS/MS system. To be able to 
quantify samples with higher concentrations than 10 000 nM, e.g. in the PK curves, it 
was necessary to also prepare standard curves with higher concentration ranges, 
although, the sample preparation was the same. 
 
3.7.3 Preparation of samples 
Analytes in spiked plasma samples were made by spiking blank rat plasma with 
compounds with preferred concentrations. Stock solutions were stored at a 
concentration of 10 mM, then diluted with ACN: H2O (50:50). These sample 
solutions were then diluted with blank plasma in new tubes (1:10). 
For single compounds, 25 µL of the plasma solution was transferred to a deep well 
plate, then precipitated with 150 µL ice cold ACN containing 200 nM Warfarin.  The 
deep well plate was vortexed for 5 minutes and centrifuged for 20 minutes. After 
centrifugation, 120 µL of the supernatant was transferred to a new deep well plate, 
and 300 µL buffer (2 % ACN in 10 mM acetic acid) was added to the supernatant. 
The samples were injected on the LC-MS/MS system. 
For pooled compounds (n =3) 75 µL (25µL x 3) of the plasma solution was 
transferred to a deep well plate, then precipitated with 200 µL ice cold ACN 
containing 200 nM Warfarin. The next steps were the same as for the single 
compounds. 
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Figure 6 Differences in sample preparation between single and pooled samples 
 
As shown later in this study, the amount of ACN used for protein precipitation for 
pooled samples was varied before the use of 200 µL was implemented as a standard 
procedure. When using 200 µL ACN in the cassette method, this correspond to a 
dilution that is 1,6 times higher than for the single samples. 
 
3.7.4 Preparation of samples from AstraZeneca in vivo PK animal studies 
At DMPK AstraZeneca R&D Södertälje, Sweden, a great number of animal studies 
are implemented. The most common test animal at this site is rat. In this study, plasma 
samples from three in vivo PK rat studies are being used for analysis. The plasma 
contains test compounds from AstraZeneca, and due to industrial restrictions, these 
compounds are referred to as AZ1, AZ2 and AZ3. 
The plasma samples are taken from the test animals at different time points to give the 
PK profile of the test compounds. In the sample preparation step, 25 µL plasma was 
precipitated with 150 µL ice cold ACN in the same way as for the spiked plasma 
samples. For the pooled samples (25 µL x 3), 200 µL ACN was used for precipitation. 






4. Results and discussion 
4.1 Introducing experiments/ Method development 
The first period at AstraZeneca was used for method development, finding MS-
methods and chromatography methods for the reference compounds. There were 
prepared standard curves for all the compounds, and then they were pooled together. 
The three basic/positive compounds (diazepam, imipramine and propranolol) and the 
three acidic/negative compounds (diclofenac, naproxen and rofecoxib) were pooled 
together in two cassette groups (n = 3) respectively, using warfarin as internal 
standard in both cassette groups. The “basic cassette” was analysed in positive ESI 
mode, whilst the “acidic cassette” was analysed in negative ESI mode. 
 
The single standards were as mentioned earlier made by transferring 25 µL of each 
standard concentration in spiked plasma to a deep well plate, then protein precipitated 
with 150 µL ice cold ACN. After vortexing and centrifugation, 120 µL of the 
supernatant was transferred to a deep well plate, and 300 µL buffer was added. The 
pooled standards were made by pooling 25 µL x 3 (25 µL of each standard 
concentration) together in the same vial. To precipitate, 450 µL ice cold ACN was 
added, and then vortexed and centrifuged. 120 µL of the supernatant was transferred 
to a deep well plate, and 300 µL buffer was added before analysis. A second pooling 
method was also performed by pooling 10 µL x 3 together, precipitated with 150 µL 
ice cold ACN, 120 µL of the supernatant was transferred to a deep well plate, and 300 
µL buffer was added. 
These samples were analysed on two different MS systems, MS PREMIER using an 
acetonitrile gradient and MS ULTIMA using a methanol ammonium acetate gradient. 
There were eight standard points, concentration range 5 – 10000 nmol/ml in spiked 
plasma (5, 16.7, 50, 166.7, 500 1666.7, 5000 and 10 000 nmol/ml). 
 
The experiments showed, as expected a loss of sensitivity with the pooled samples 
because of extra diluting when pooling them together. Table 4.1-1 shows a summary 





Single vs. Pooled        
         
1:   25 µL plasma std + 150 µL ACN     
2:   25 µL plasma std x 3 + 450 µL ACN    
3:   10 µL plasma std x 3 + 150 µL ACN     
         
  8 std points, range 5 - 10000 nmol/L   
         
         
  Acetonitrile gradient MS:PREMIER MeOH amm.acetat gradient MS:ULTIMA 
  Single Pool 3x25 Pool 3x10   Single Pool 3x25 Pool 3x10  
Diazepam 5 16.7 5   16.7 16.7 16.7  
Imipramine 5 50 16.7   5 16.7 16.7  
Propranolol 5 50 16.7   5 16.7 16.7  
                 
Diclofenac 5 5 5   16.7 16.7 16.7  
Naproxen 5 16.7 16.7   5 16.7 16.7  
Rofecoxib 5 16.7 50   16.7 16.7 16.7  
Standard conc.: 5, 16.7, 50, 166.7, 500, 1666.7, 5000, 10000    
 Table 4.1-1 LOQ for standard curves, comparing single vs. pooled samples 
 
4.2 Formulation experiments 
The formulation solutions used in this experiment were Meglumine (used for 
diclofenac and naproxen), Gluconic acid (used for imipramine and propranolol) and 
Cyclodextrine (used for diazepam and rofecoxib). 
The formulations were prepared by spiking 5 % directly in blank plasma. 
 
4.2.1 Pre-experiment using imipramine and gluconic acid 
Standard curve for imipramine in blank plasma was obtained. The standard 
concentrations were 5, 10, 34, 113, 375, 1250, 3333, and 10 000 nmol/ml. Quality 
controls (QC) were made of the concentrations 113 nmol/ml (low control), 1250 
nmol/ml (medium control) and 10 000 nmol/ml (high control). There were six of each 
controls taken from the same plasma vial, but placed in 6 different wells on the deep 
well plate. The controls contained formulation (gluconic acid), whereas the standard 
curve did not. 
 
This experiment was performed at Waters Corporation in Sollentuna, Sweden, using a 
Quattro Premier mass spectrometer with an UPLC. Table 4.2.1-1 shows the 
summarized result from this experiment. The results from the standard curve show 
 29 
some variation, but are overall quite good. The percentage deviation are varying from 
–18,25 % to 36,01%. In order to go further with the results at AstraZeneca, this 
variation generally should not exceed ± 25%, and this limit were also set as the 
general acceptance criterion for deviations between single and pooled samples in this 
study. The results from the controls falls within this range with a good margin, 
percentage deviation varying from –8,42% (low control), -7,27% (high control) to 




values [nM] Area 
Measured 
values [nM] %Dev 
imipramine1 Standard 5.06 356 6.68 32.05 
imipramine2 Standard 10.13 993 8.28 -18.25 
imipramine3 Standard 33.75 2654 21.57 -36.1 
imipramine4 Standard 112.5 7460 92.39 -17.85 
imipramine5 Standard 375 23429.5 362.19 -3.4 
imipramine6 Standard 1250 87829.5 1355.74 8.45 
imipramine7 Standard 3333.33 191853.5 3273.32 -1.8 
imipramine8 Standard 10000 583780.5 10004.21 0 
            
low control QC 112.5 9338 103.03 -8.42 
            
medium control QC 1250 96851.83 1416.21 13.3 
            
high control QC 10000 505360.5 9271.7 -7.27 
Table 4.2.1-1 Imipramine standard curve with quality controls (QC) containing 
formulation 
 
4.2.2 Pre-experiment, pooling diazepam, diclofenac and propranolol 
This was an experiment to detect the limits of quantification (LOQ) by pooling both 
basic and acidic compounds, and to compare the difference in LOQ of three single 
compounds vs. the same compounds pooled together. The compounds pooled together 
were diazepam and propranolol, which are basic and diclofenac, which is acidic. 
These compounds were pooled together with formulations, cyclodextrine for 
diazepam, meglumine for diclofenac, and gluconic acid for propranolol. Both standard 
curves and controls contained formulations, and because of the pooling, each pooled 
sample would contain all three formulations. 
As expected, the LOQ were higher when the compounds were pooled together. The 
LOQ was also higher when pooling both basic and acidic compounds together 
compared with pooling only basic or acidic compounds. Now, the LOQ for the pooled 
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compounds was in the range between 30 – 100 nM/ml. (When pooling only basic or 
acidic compounds, this range was between 5-50 nM/ml). 
But still, the results were acceptable with a accuracy within ±25% for all 
concentration levels, these results are summarized in table 4.2.2-1. 
 
 Discrete/ Single Cassette/ Pool 
Diazepam 98% - 116% 85% - 125% 
Diclofenac 100% - 115% 90% - 114% 
Propranolol 95% - 108% 94% - 118% 
Table 4.2.2-1 Discrete vs. cassette accuracy (%), concentration levels 34 nM – 3330 
nM, positive/negative switching mode 
 
4.3 Sample preparation development -LOQ 
There is an increase of LOQ due to the diluting in the sample preparation step when 
pooling compounds together. In standard single sample preparation, 25 µL spiked 
plasma is precipitated with 150 µL ice cold ACN, after precipitation, 120 µL of the 
supernatant is mixed with 300 µL buffer before analysis. When pooling, 25 µL of 
each compound in spiked plasma, n =3 (25 µL x3) are pooled, then precipitated with 
450 µL ice cold ACN. Then again, 120 µL of the supernatant is mixed with 300 µL 
buffer prior to the analysis. This corresponds to a dilution that is 3 times higher for the 
pooled samples than for the single samples. 
To reduce the loss of sensitivity, the volumes in the sample preparation needed to be 
changed. 
 
4.3.1 Reducing the amount of acetonitrile used for protein precipitation 
This experiment was performed with the two cassette groups, the acidic and the basic 
cassette. 
Together with the standard sample preparation method when pooling, two new 
methods using less ACN were performed: 
 
A) standard AZ method:  450 µL ACN (25 µL x3 spiked plasma + 450 µL ACN → 
120 µL supernatant + 300 µL buffer) 
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B) alternative 1:  300 µL ACN (25 µL x3 spiked plasma + 300 µL ACN → 120 µL 
supernatant + 300 µL buffer) 
 
C) alternative 2:  200 µL ACN (25 µL x3 spiked plasma + 200 µL ACN → 120 µL 
supernatant + 300 µL buffer) 
 
These experiments were performed both with and without formulation solutions ( 5% 
cyclodextrine, gluconic acid and meglumine in plasma). 
The samples were analysed on the two-column system Quattro Ultima using two 
different methods (total duration of each analysis 4.25 min and 7.50 min respectively). 
The parameters for these methods are shown in table 4.3.1-1. 
 
Column 1         Column 2         
Loading Pump    Eluting Pump     
Isocratic     Binary      
A: 15% meOH in 10 mM amm.acetat A: 15% meOH in 10 mM amm.acetat 
B: meOH         B: 85% meOH in 10 mM amm.acetat 
 
Time between injections: 4.25 min 
  Start Sec Flow Comp SD CD Valve D Flow Grad % B Comments 
0/1 0.00 60 1.00 A Load → N/A 0.40 Step 20.0 
Load Sample and Discard 
Plasma 
2 1.00 60 1.00 A Elute → N/A 0.40 Ramp 100.0 Elute sample to detector 
3 2.00 90 1.00 A Elute → N/A 0.40 Ramp 100.0 Elute sample to detector 
4 3.50 30 1.00 B Load → N/A 0.40 Step 20.0 Clean column + re-equilibrate 
5 4.00 15 1.00 A Load → N/A 0.40 Step 20.0 Clean column + re-equilibrate 
 
Time between injections 7.50 min 
  Start Sec Flow Comp SD CD Valve D Flow Grad % B Comments 
0/1 0.00 120 1.00 A Load → N/A 0.35 Step 20.0 
Load Sample and Discard 
Plasma 
2 2.00 60 1.00 A Elute → N/A 0.35 Ramp 90.0 Elute sample to detector 
3 3.00 180 1.00 A Elute → N/A 0.35 Ramp 90.0 Elute sample to detector 
4 6.00 60 1.00 B Load → N/A 0.35 Step 20.0 Clean column + re-equilibrate 
5 7.00 30 1.00 A Load → N/A 0.35 Step 20.0 Clean column + re-equilibrate 




This was an important experiment for further method development. The result showed 
that the response (area) was higher when adding less ACN in the sample preparation, 
and hence the LOQ was better (lower).  
The area of the chromatography peaks for the internal standard (warfarin) decreased 
as expected when adding less ACN. (The ACN used in the experiment for protein 
precipitation always contained 200 nm warfarin).  
Adding formulations to the samples gave little impact on the results compared to the 
samples without formulation, but there were some variations. 
The percentage deviations between the total area for the reference compounds with 
and without formulation are summarized in table 4.3.1-2,  4.3.1-3 and 4.3.1-4. 
 
450 µL ACN: 
Compound 4.25 minute method 7.50 minute method 
Diazepam -1% -7% 
Imipramine 13% 12% 
Propranolol 0% -8% 
Diclofenac 26% 8% 
Naproxen 27% 14% 
Rofecoxib 16% 9% 
Table 4.3.1-2 Deviation from standard curves without formulation 
 
 
300 µL ACN: 
Compound 4.25 minute method 7.50 minute method 
Diazepam 1% 12% 
Imipramine -43% 72% 
Propranolol 1% 13% 
Diclofenac -10% -7% 
Naproxen 8% -16% 
Rofecoxib -24% -13% 




200 µL ACN: 
Compound 4.25 minute method 7.50 minute method 
Diazepam 6% 20% 
Imipramine 25% 78% 
Propranolol 8% 7% 
Diclofenac -1% 18% 
Naproxen -28% -6% 
Rofecoxib -51% -5% 
Table 4.3.1-4 Deviation from standard curves without formulation  
 
As shown in table 4.3.1-2,  4.3.1-3 and 4.3.1-4, which shows the percentage 
difference when adding formulation, the impact is quite small for most of the 
substances, imipramine though shows a greater variation. The deviations diversifies in 
both positive and negative manner, it is therefore difficult to say if the formulations 
give suppression or enhancement. But overall, the deviations are small, they do not 
appear to be systematic, and the variations seem to be occasional. 
Other results from this part of the study can be found in Appendix A. 
 
Figure 7 illustrates the summarized area of the pooled standard curves for the 
compound propranolol comparing the amount of ACN added in the protein 
precipitation. As shown in the figure, the response/ area increased when adding less 










450 µL ACN 300 µL ACN 200 µL ACN
Total area, Propranolol
no form. 4 min
with form. 4 min
no form. 8 min
with form. 8 min
 
Figure 7 Summarized area of propranolol with different amounts of ACN added in 
the sample preparation 
 
Table 4.3.1-5 shows the LOQ for all the reference compounds in the 4.25 min method 
both with and without formulation also considering the amount of ACN added in the 
sample preparation. 
 
Standard concentrations: 5-10-34-113-375-1250-3333-10 000 (nmol/L) 
LOQ [nM] No formulation With formulation 
Amount of ACN 450µL 300µL 200µL 450µL 300µL 200µL 
Diazepam 5 5 5 5 5 5 
Imipramine 5 5 5 5 5 5 
Propranolol 5 5 5 5 5 5 
 
Diclofenac 5 5 5 34 5 5 
Naproxen 34 10 5 34 5 5 
Rofecoxib 34 34 5 34 5 5 
Table 4.3.1-5 LOQ (nmol/L) for the reference compounds with and without 
formulation, different amounts of ACN added in the sample preparation 
 35 
As shown in the table, the lowest standard concentration (5 nmol/L) can be detected 
for all the compounds both with and without formulation when adding the lowest 
amount of ACN (200 µL) in the sample preparation. Even though there are some 
small variations, the formulations did not seem to affect the results. This experiment 
involved that 200 µL ACN was set to be used in the sample preparation of pooled 
samples. 
 
4.4 Pharmakokinetic profiles 
Pharmacokinetics (PK) is the study of rate processes such as absorption, distribution 
and excretion of a drug and the multiple relationships that affects the drug. PK 
describes the quantitative relationship between administrated doses and dosing 
regimens and the observed plasma levels of a drug. The drug can be administered to 
the test animal in several ways, in this study we will go further into the PK profiles 
from the oral (PO) and intravenous (IV) route [7]. 
 
4.4.1 Pre-check, PK profiles of the basic reference compounds, PO route 
In this experiment, plasma samples were spiked with the basic reference compounds 
(diazepam, imipramine and propranolol) corresponding to the concentrations of 
literature PK values as described in methods and experimental. The samples were 
analysed both in discrete/single and cassette/pooled mode. 
Eight time points for the literature PK values were chosen, administered via the oral 
route. Standard sample preparation was followed, 25µL spiked plasma was 
precipitated with 150 µL ice cold ACN, 120 µL of the supernatant was mixed with 
300 µL buffer (mobile phase) before analysis. For the pooled samples, 75 µL (25 µL 
x 3) spiked plasma was precipitated with 200 µL ice cold ACN, 120 µL of the 
supernatant was mixed with 300 µL buffer.  
MS instrumentation used for this experiment was the two-column system Quattro 
Ultima, using a 4.25 min method, similar to the method used for reducing the amount 
of ACN in the sample preparation. 
The results are summarized in table 4.4.1-1 showing the measured concentrations for 





Diazepam:   
Time (h) Literature conc.[nM] Measured conc.[nM] Single Measured conc.[nM] Pool 
0.25 650 709 725 
0.5 750 804 835 
0.75 700 760 724 
1 650 718 686 
1.5 450 442 397 
2.5 220 418 351 
6 25 48 45 
24 5 7 9 
    
    
Imipramine:   
Time (h) Literature conc.[nM] Measured conc.[nM] Single Measured conc.[nM] Pool 
0.25 360 403 453 
0.5 270 329 332 
0.75 430 535 535 
1 270 297 341 
1.5 270 313 347 
2.5 230 284 270 
6 150 185 160 
24 70 95 95 
    
    
Propranolol:   
Time (h) Literature conc.[nM] Measured conc.[nM] Single Measured conc.[nM] Pool 
0.25 280 374 432 
0.5 160 204 254 
0.75 100 125 170 
1 60 83 109 
1.5 40 51 69 
2.5 20 26 27 
6 8 12 12 
24 0 0 0 
Table 4.4.1-1 PK concentrations showing literature, single and pooled values for the 
basic reference compounds, PO route 
 
There are some variations in the measured concentrations compared to the literature 
concentration values, all over, the literature values are lower than the measured values 
for both single and pooled compounds. Although, the deviations between single and 
pooled samples are small. This is illustrated in figure 8 and 9 where the literature, 























Figure 8 Comparing diazepam PK concentrations for literature, single and pooled 

















Figure 9 Comparing imipramine PK concentrations for literature, single and pooled 
values, PO route 
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The results of the deviation between single and pooled samples are summarized in 
table 4.4.1-2 showing the percentage deviation from the single samples. 
 
 
Time (h) Diazepam Imipramine Propranolol 
0.25 2%  11%  13%  
0.5 4%  1%  20%  
0.75 -5%  0%  27%  
1 -5%  13%  23%  
1.5 -11%  10%  26%  
2.5 -19%  -5%  2%  
6 -6%  -16%  -5%  
24 24%  0%  0%  
Table 4.4.1-2 PK profiles, pooled concentrations values, deviation from single 
concentration values, PO route 
 
The results show only small variations between the single and pooled measured 
values. The variations for diazepam vary from –11% to 24%, for imipramine –16% to 
13%, and for propranolol –5% to 27%. 
 
4.4.2 PK profiles of the acidic reference compounds, PO route 
As in the previous experiment with the basic compounds, the plasma samples were 
now spiked with the acidic reference compounds (diclofenac, naproxen and rofecoxib) 
corresponding to the concentrations of literature PK values as described in methods 
and experimental. The samples were analysed both in discrete/single and 
cassette/pooled mode. 
MS instrumentation used for this experiment was a one-column system Quattro 
Ultima, using a 4 min method with an acetonitrile gradient.  
The results are summarized in table 4.4.2-1  showing the measured concentrations for 









Diclofenac:   
Time (h) Literature conc.[nM] Measured conc.[nM] Single Measured conc.[nM] Pool 
0.25 3000 3751 3392 
0.50 2000 2518 2616 
0.75 1500 1998 1830 
1.00 1000 1119 1097 
1.50 800 954 946 
2.50 650 737 605 
6.00 400 415 461 
24.00 10 41 25 
    
    
Naproxen:    
Time (h) Literature conc.[nM] Measured conc.[nM] Single Measured conc.[nM] Pool 
0.25 35000 28174 26882 
0.50 43000 34490 34386 
0.75 43000 30069 32582 
1.00 43000 36473 38203 
1.50 45000 39000 38063 
2.50 45000 38872 36385 
6.00 40000 35631 39091 
24.00 3000 3149 2866 
    
    
Rofecoxib:   
Time (h) Literature conc.[nM] Measured conc.[nM] Single Measured conc.[nM] Pool 
0.25 70 62 34 
0.50 150 106 191 
0.75 270 194 233 
1.00 300 268 284 
1.50 450 390 345 
2.50 600 502 438 
6.00 450 403 428 
24.00 70 50 49 
Table 4.4.2-1 PK concentrations showing literature, single and pooled values for the 
acidic reference compounds, PO route 
 
 
As for diazepam, imipramine and propranolol, the literature concentration values were 
a little lower than the measured single and pooled concentration values for diclofenac, 
but for naproxen and rofecoxib, it was the other way around. This is illustrated in 























Figure 10 Comparing diclofenac PK concentrations for literature, single and pooled 





















Figure 11 Comparing naproxen PK concentrations for literature, single and pooled 
values, PO route 
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Although, the difference between the literature and the single/pooled values were not 
very large, what is interesting are the relative small difference between the single and 
the pooled concentration values. 
 
The deviations between the single and pooled samples for the acidic cassette are listed 
in table 4.4.2-2. As shown in the table, three values exceed the ±25% acceptance 




Time (h) Diclofenac Naproxen Rofecoxib 
0.25 -11%  -5%  -82%  
0.5 4%  0%  45%  
0.75 -9%  8%  17%  
1 -2%  5%  6%  
1.5 -1%  -2%  -13%  
2.5 -22%  -7%  -15%  
6 10%  9%  6%  
24 -64%  -10%  -2%  
Table 4.4.2-2 PK profiles, pooled concentrations values, deviation from single 
















4.4.3 PK curves, PO route, compilation 
The PK parameters and the PK curves for all the reference compounds are shown in 
table 4.3.1-1 to table 4.4.1-12 and in figure 13 – 18. The figures illustrates the 
estimated PO route for three trials analysed both on UPLC and HPLC in both discrete 
and cassette mode. 
 
 











Figure 12 PK- parameters 
 
 
Cmax is the highest concentration in the PK curve, T1/2 is the biological half time. Tmax 
is the time point where the concentration is highest (Cmax) and AUClast refers to the 
“area under curve”, the area under the PK curve plotted in the diagram.  
 
When looking at the PK parameters, the reader should have in mind, that for the PO 
route, the important parameters are Cmax, T1/2 and AUC, whilst for the IV route, the 














  T1/2 (h) Cmax (nM) Tmax (h) AUClast AUCinf_pred AUCextr V_F (L/kg) CL_F (L_kg) 
Literature  4.7 750 0.5 1737 1766 1.7 38.3 5.7 
Trial 1 Single 4.6 784 0.5 1808 1842 1.9 36.1 5.4 
 Pooled 5.0 728 0.5 2005 2060 2.7 34.9 4.9 
Trial 2 Single 4.3 804 0.5 2356 2394 1.6 25.7 4.2 
 Pooled 4.9 835 0.5 2225 2282 2.5 30.7 4.4 
Trial 3 Single 4.4 979 0.5 2355 2388 1.4 26.6 4.2 
 Pooled 4.6 1067 0.5 2532 2573 1.6 25.9 3.9 






































Figure 13 PK curves for diazepam, PO route 
 
 
Deviation from Single 
  T1/2 (h) Cmax (nM) Tmax (h) AUClast AUCinf_pred V_F (L/kg) CL_F (L_kg) 
Trial 1  8% 7% 0% 11% 12% 3% 11% 
Trial 2  14% 4% 0% 6% 5% 20% 5% 
Trial 3  5% 9% 0% 8% 8% 2% 7% 
Table 4.4.3-2 PK parameters for diazepam, deviation from single, PO route 
 
Diazepam show very small variations between single and pooled samples, all the PK 





  T1/2 (h) Cmax (nM) Tmax (h) AUClast AUCinf_pred AUCextr V_F (L/kg) CL_F (L_kg) 
Literature  13.6 430 0.75 3226 4566 29.4 214.4 11.0 
Trial 1 Single 15.4 500 0.75 3620 5503 34.2 201.9 9.1 
 Pooled 14.5 371 0.75 2877 4163 30.9 250.5 12.0 
Trial 2 Single 14.9 535 0.75 4041 6025 32.9 178.1 8.3 
 Pooled 13.4 648 0.75 4356 6112 28.7 158.6 8.2 
Trial 3 Single 14.0 468 0.75 3723 5333 30.2 189.2 9.4 
 Pooled 13.5 405 0.75 3476 4920 29.4 198.6 10.2 







































Figure 14 PK curves for imipramine, PO route 
 
 
Deviation from Single 
 T1/2 (h) Cmax (nM) Tmax (h) AUClast AUCinf_pred V_F (L/kg) CL_F (L_kg) 
Trial 1 6% 26% 0% 21% 24% 24% 32% 
Trial 2 10% 21% 0% 8% 1% 11% 1% 
Trial 3 3% 13% 0% 7% 8% 5% 8% 
Table 4.4.3-4 PK parameters for imipramine, deviation from single, PO route 
 
For imipramine, there seem to be a little variation between single and pooled samples 
looking at the PK curves. But, looking at the PK parameters, the deviations between 





  T1/2 (h) Cmax (nM) Tmax (h) AUClast AUCinf_pred AUCextr V_F (L/kg) CL_F (L_kg) 
Literature  2.1 280 0.25 239 262 8.8 263.5 87.6 
Trial 1 Single 0.8 248 0.25 191 209 8.2 125.6 110.3 
 Pooled 2.2 222 0.25 198 220 9.9 337.3 104.7 
Trial 2 Single 1.8 343 0.25 300 321 6.5 181.8 71.6 
 Pooled 2.0 432 0.25 377 407 7.5 159.1 56.5 
Trial 3 Single 2.5 301 0.25 242 273 11.3 308.6 84.3 
 Pooled 2.5 169 0.5 209 242 13.7 349.8 95.1 










































Figure 15 PK curves for propranolol, PO route 
 
 
Deviation from Single 
  T1/2 (h) Cmax (nM) Tmax (h) AUClast AUCinf_pred V_F (L/kg) CL_F (L_kg) 
Trial 1  183% 10% 0% 3% 5% 168% 5% 
Trial 2  11% 26% 0% 25% 27% 13% 21% 
Trial 3  0% 44% 100% 14% 11% 13% 13% 
Table 4.4.3-6 PK parameters for propranolol, deviation from single, PO route 
 
For propranolol, there are some variations between single and pooled samples as 
shown in the PK curves and in the PK parameters. The deviations do not appear to be 




  T1/2 (h) Cmax (nM) Tmax (h) AUClast AUCinf_pred AUCextr V_F (L/kg) CL_F (L_kg) 
Literature  3.5 3000 0.25 6610 6662 0.8 7.6 1.5 
Trial 1 Single 5.2 3751 0.25 8412 8719 3.5 8.7 1.1 
 Pooled 4.5 3392 0.25 7898 8066 2.1 8.1 1.2 
Trial 2 Single 3.5 2334 0.25 5485 5527 0.8 9.1 1.8 
 Pooled 3.6 3430 0.25 7245 7308 0.9 7.1 1.4 
Trial 3 Single 3.3 3151 0.25 6493 6531 0.6 7.4 1.5 
 Pooled 3.7 2592 0.25 5791 5846 0.9 9.1 1.7 







































Figure 16 PK curves for diclofenac, PO route 
 
 
Deviation from Single 
  T1/2 (h) Cmax (nM) Tmax (h) AUClast AUCinf_pred V_F (L/kg) CL_F (L_kg) 
Trial 1  13% 10% 0% 6% 7% 6% 8% 
Trial 2  3% 47% 0% 32% 32% 22% 24% 
Trial 3  10% 18% 0% 11% 10% 23% 12% 
Table 4.4.3-8 PK parameters for diclofenac, deviation from single, PO route 
 
The PK curves for diclofenac show very little variation between single and pooled 
samples. In trial 2, some of the PK parameters exceeds the acceptance criterion, the 
reason for this is the heavy slope in the beginning of the PK curve, where small 





































Figure 17 PK curves for naproxen, PO route 
 
Deviation from Single 
  T1/2 (h) Cmax (nM) Tmax (h) AUClast AUCinf_pred V_F (L/kg) CL_F (L_kg) 
Trial 1  3% 0% 300% 2% 1% 5% 1% 
Trial 2  12% 12% 67% 5% 3% 14% 2% 
Trial 3  16% 3% 70% 1% 5% 12% 5% 
Table 4.4.3-10 PK parameters for naproxen, deviation from single, PO route 
 
The differences between single and pooled samples for naproxen are all over small. 
The reason for the great variations for the Tmax is because this parameter comes very 
early in the PK curve, and the values are very small. Therefore, small variations in the 
time for Tmax will give a great influence on the deviation between single and pooled 
samples. As mentioned earlier, Tmax is not an important parameter in the PO route. 
  T1/2 (h) Cmax (nM) Tmax (h) AUClast AUCinf_pred AUCextr V_F (L/kg) CL_F (L_kg) 
Literature  5.3 45000 1.5 508320 531781 4.4 0.1 0.0 
Trial 1 Single 5.6 39000 1.5 456823 483269 5.5 0.2 0.0 
 Pooled 5.5 39091 6 466150 489774 4.8 0.2 0.0 
Trial 2 Single 6.5 26336 1.5 325806 354023 8.0 0.3 0.0 
 Pooled 5.8 29426 2.5 342796 363796 5.8 0.2 0.0 
Trial 3 Single 6.7 27925 2.5 346813 379965 8.7 0.3 0.0 
 Pooled 5.6 28836 0.75 342747 362493 5.4 0.2 0.0 
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Rofecoxib: 




































Figure 18 PK curves for rofecoxib, PO route 
 
 
Table 4.4.3-12 PK parameters for rofecoxib, deviation from single, PO route 
 
 
Like most of the other reference compounds, there are only small deviations between 
single and pooled samples for rofecoxib. 
  T1/2 (h) Cmax (nM) Tmax (h) AUClast AUCinf_pred AUCextr V_F (L/kg) CL_F (L_kg) 
Literature  6.9 600 2.5 6373 7066 9.9 14.0 1.4 
Trial 1 Single 6.3 502 2.5 5357 5811 7.9 15.6 1.7 
 Pooled 6.4 437.5 2.5 5356 5807 8.0 15.9 1.7 
Trial 2 Single 7.3 730 2.5 6728 7642 11.7 13.8 1.3 
 Pooled 8.4 531 2.5 6254 7360 15.0 16.5 1.4 
Trial 3 Single 5.7 807 2.5 7532 8030 6.2 10.2 1.2 
 Pooled 7.3 536 2.5 6119 6893 11.3 15.4 1.4 
Deviation from Single 
  T1/2 (h) Cmax (nM) Tmax (h) AUClast AUCinf_pred V_F (L/kg) CL_F (L_kg) 
Trial 1  2% 13% 0% 0% 0% 2% 0% 
Trial 2  16% 27% 0% 7% 4% 20% 4% 
Trial 3  29% 34% 0% 19% 14% 50% 16% 
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In this study, one of the main goals was that the deviation between single and pooled 
samples should not exceed ±25 %. However, for some reference compounds, 
occasional deviations >25% are observed, but this does not appear to be systematic.  
 
4.5 AstraZeneca in vivo animal studies 
Three AstraZeneca Animal (rat) studies were chosen to study PK profiles further. 
These studies consisted of one compound in each study, totally three compounds. 
Each compound had been dosed to a rat; three rats were given the same compound, 
which means that there were totally nine series. In each study, the AZ compound were 
dosed to three rats via the PO route, three rats via the IV route, and also to three rats 
as an infusion. In this part of the study, we will only go further into the PO route. The 
dose given to the test animals were 10 µmol/kg for the PO route in all studies. 
 
Blood samples were taken from the rats after dosing at these time intervals:  
 
15 min – 30 min – 45 min – 60 min – 1,5 h – 2,5 h – 6 h and 24 h after dosing. 
 
The three AstraZeneca compounds are in this report referred to as AZ1, AZ2 and 
AZ3. The molecular weights of these compounds are respectively 351.32, 360.46 and 
474.26. Table 4.5-1 is showing the MS methods/ MRM-scan transitions for the 
compounds. 
 
Compound Parent (m/z) Daughter (m/z) CV (V) CE (eV) Ion mode 
1) AZ1 352.01 173.00 46 22 ES+ 
2) AZ2 361.13 219.94 37 34 ES+ 
3) AZ3 473.98 190.03 46 28 ES+ 
Warfarin (IS) 308.88 163.1 18 16 ES+ 
Table 4.5-1 MS methods/ MRM-scan transitions for the AstraZeneca compounds 
 
4.5.1 Standard curves 
In the first experiment, standard curves for the three compounds were made, also as a 
cassette. The standard concentrations were 5, 10, 34, 112.5, 375, 1250, 3333 and 
10000 nM. The samples were analysed on the mass spectrometer Quattro Ultima, a 2-
column system using a meOH gradient. Total duration time for one analysis was app. 
4 minutes. 
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The results were satisfying; figure 19 shows a typical response- and residual graph of 
the standard curve of compound AZ2. Figure 20 shows the chromatogram for the 
same compound together with the chromatogram for the internal standard, warfarin. 
The retention time for AZ2 was 3.01 min and 2,62 min for warfarin. 
 The maximum deviation from the theoretical values was –7% for this compound. For 
the compounds AZ1 and AZ3, the maximum deviation were respectively 4,6% and 
14,3%. The lowest standard concentration value (5 nM) for the compound AZ1 was 
below the LOQ, and had to be excluded from the standard curve. For the pooled 
standard curve, the maximum deviation from the theoretical values were 9,3%, 11,8% 




Figure 19 Standard curve, compound AZ2, the residual graph shows the deviation for 






Figure 20 HPLC chromatogram for compound AZ2 with IS (warfarin) using a 
Hypurity C-18 column 
 
The comparison of the results between single and pooled samples is shown in table 
4.5.1-1. The percentage deviation is listed at the right of each table; the values are 
marked with a green colour because they all are satisfying and fall within the 
acceptance criterion of  ±25 % deviation between single and pooled samples. The 
















AZ1     AZ2    
Theory Single Pool   Theory Single Pool  
5 NV NV NV * 5 5.2 4.9 -6% 
10 10.1 9.8 -3%  10 9.3 10.7 13% 
34 32.5 37.2 13%  34 34 33.1 -3% 
112 113.5 106.7 -6%  112 106.6 103.3 -3% 
375 369.3 362 -2%  375 389.9 366.4 -6% 
1250 1307.3 1312 0%  1250 1311 1397.7 6% 
3333 3292.2 3165 -4%  3333 3358.2 3254.9 -3% 
10000 9994.6 10126.4 1%  10000 9867.5 9905 0% 
*These values were below LOQ       
  
AZ3    
Theory Single Pool  
5 5.1 5.3 4% 
10 9.5 9 -6% 
34 33.8 33.1 -2% 
112 105.7 110.2 4% 
375 351.4 356.8 2% 
1250 1428.5 1397 -2% 
3333 3429.3 3496 2% 
10000 9719.1 9671.6 0% 
 Table 4.5.1-1 Comparison of single and pooled standard curve values for the 
compounds AZ1, AZ2 and AZ3 
 
4.5.2 Single vs. pooled, PO route 
Formulations used in the AZ studies were 5% dimethyl acetamide (DMA) in 20% 
cyclodextrine in water for AZ1 and AZ2. For AZ3, the formulation solution used were 
5% DMA in 95% cyclodextrine.  
 
Although, the most interesting from this experiment is the difference between single 
and pooled samples. These results are listed in table 4.5.2-1 and 4.5.2-2, showing the 
percentage deviation between single and pooled samples of the AZ compounds in 









Deviation from single 1       
 AZ1-rat 4 AZ1-rat 5 AZ1-rat 6   AZ2-rat 4 AZ2-rat 5 AZ2-rat 6 
Time(h) Pool1 Pool1 Pool1  Time(h) Pool1 Pool1 Pool1 
15min -7% 15% NV  15min -31% 0% 1% 
30min -2% 23% 21%  30min -38% 9% -7% 
45min -1% 20% 26%  45min -40% -19% -13% 
1h 3% 10% 27%  1h -8% 0% 0% 
1.5h 13% 7% 38%  1.5h -8% -28% -13% 
2.5h 16% 1% 33%  2.5h -9% -13% -2% 
6h 18% 6% 33%  6h -18% -20% 0% 
24h 0% 0% 0%  24h 0% 0% 0% 
 
 AZ3-rat 4 AZ3-rat 5 AZ3-rat 6 
Time(h) Pool1 Pool1 Pool1 
15min -4% -4% 19% 
30min -18% 17% 7% 
45min -28% 1% 13% 
1h -24% 2% 10% 
1.5h 1% -8% 12% 
2.5h -6% -1% 14% 
6h -1% 11% 1% 
24h 0% 0% 0% 
Table 4.5.2-1 Percentage deviation between single and pooled AZ compounds (AZ1, 


















Deviation from single 2       
 AZ1-rat 4 AZ1-rat 5 AZ1-rat 6   AZ2-rat 4 AZ2-rat 5 AZ2-rat 6 
Time(h) Pool2 Pool2 Pool2  Time(h) Pool2 Pool2 Pool2 
15min 5% 5% NV  15min -17% 0% 5% 
30min 7% 4% 18%  30min -29% -19% -19% 
45min 9% 5% 13%  45min -17% -48% -33% 
1h 16% 1% 14%  1h -27% 0% 0% 
1.5h 10% 5% 33%  1.5h -26% -35% -8% 
2.5h 0% 11% 13%  2.5h -40% -24% 10% 
6h 3% 3% 2%  6h -30% -18% -6% 
24h 0% 0% 0%  24h 0% 0% 0% 
 
 AZ3-rat 4 AZ3-rat 5 AZ3-rat 6 
Time(h) Pool2 Pool2 Pool2 
15min -7% 2% 11% 
30min -8% 4% 8% 
45min -10% -21% 11% 
1h 5% 4% 1% 
1.5h -13% 7% -13% 
2.5h -14% -7% -7% 
6h -16% 15% -1% 
24h 0% 0% 0% 
Table 4.5.2-2 Percentage deviation between single and pooled AZ compounds (AZ1, 
AZ2 and AZ3) in the second run 
 
The results are overall quite satisfying, but there are some variations between the 
single and pooled samples. For the compound AZ1, the pooled values are overall 
higher than for the single values. But for the compound AZ2, the concentration values 
are overall lower than for the single concentration values, and as for the last 
compound, AZ3 there are more variations in the way the pooled values differs from 
the single values. For animal 4 (rat 4), the values are overall lower for the pooled 
values than for the single values, for animal 5, there are higher values for pooled 
samples, and for animal 6, the values are for the most higher for the pooled samples 
than for the single samples. 
Also, looking at the differences between the two runs, it seems that the values drop 
some in the second run. This results in both “better” and “worse” values for the 
pooled samples in the second run compared with the single values, since there are 
differences in both ways. In other words, when pooled values that are higher than the 
single values drops some, they get closer to the single values and hence, they are 
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“better”, but when pooled values that are lower than the single values drops even 
more, they get further away from the single values, and hence, they become worse. 
Considering that there are some variations in the analysis system (differences between 
runs), the results between the single and pooled samples are acceptable, most of the 
values fall within the limit of ±25 % deviation. 
 
4.5.3 PK parameters, compilation, single vs. pooled, PO route 
From the values of each time point in the PK profile, there were some variations 
between the single and pooled samples, even though most of the values fulfilled the 
acceptance criterion. But, if we look at the most important PK parameters for the PO 
route (AUC, Cmax and T1/2), the deviations between single and pooled samples are 
very small. For instance, the average deviations between single and pooled samples 
for the substance AZ1 were 2% for AUC, 9% for Cmax and –2% for T1/2. This is 
illustrated in table 4.5.3-1 and figure 21– 23, comparing the deviations between PK 
parameters for single and pooled samples. 
 
 
AUC   AZ1  AZ2  AZ3  
average Discrete 925.7 154.8 1703.8 
  Cassette 949.2 141.2 2077.3 
stdev Discrete 25.5 26.3 373.9 
  Cassette 113.3 33.3 693.8 
     
Cmax   AZ1  AZ2  AZ3  
average Discrete 380.7 57.7 643.7 
  Cassette 418.7 55.7 709.3 
stdev Discrete 2.5 16.2 100.4 
  Cassette 50.1 17.7 84.5 
     
T1/2 (h)   AZ1  AZ2  AZ3  
average Discrete 3.9 4.0 3.3 
  Cassette 3.8 4.1 3.2 
stdev Discrete 1.1 0.9 1.7 
  Cassette 0.7 1.3 1.4 
Table 4.5.3-1 Average PK parameters for the AZ substances AZ1, AZ2 and AZ3, 
both discrete and cassette mode 
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Figure 21 Comparing AUC between single and pooled samples for the AZ 
compounds AZ1, AZ2 and AZ3 
 

















Figure 22 Comparing Cmax between single and pooled samples for the AZ compounds 



















Figure 23 Comparing T1/2 between single and pooled samples for the AZ compounds 
AZ1, AZ2 and AZ3 
 
 
As shown in figure 21 – 23, the deviations between single and pooled samples for the 
AZ compounds are very small. All the deviations pass the acceptance criterion of 
±25% . The largest deviation is the AUC parameter for compound AZ3, where the 
deviation between single and pooled samples is 18 %. 
 
4.5.4 Deviations between runs, PO route 
The plasma samples from the three rat studies were analysed together with spiked 
plasma standard curves. The samples were analysed both in discrete- and cassette 
mode. There were three serials in each study (animal 4, animal 5 and animal 6). 
Animal 4 from the one study were pooled together with animal 4 from the other 
studies, animal 5 from each study were pooled together, and also animal 6 from each 
study were placed in the same cassette group. These PK profiles from the test 
compounds were dosed to the test animals via the PO route. 
The samples were analysed on the same LC-MS system as the standard curves, 
Quattro Ultima, 1 column system using a meOH gradient. The same analysis plate 
were analysed twice with approximately a 24-hour interval between the two runs 
(serial 1 and serial 2). 
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First, a comparison between the two runs was made (serial 1 serial 2). The deviations 
between measured concentrations of the single series are listed in table 4.5.4-1. The 
results were satisfying with a maximum deviation at 19 %. Overall it seemed that the 
second run (single 2) gave a slightly higher concentration response even though the 
values varied both ways. One explanation to this could be that some of the sample 
could have evaporated when stored in the sample organizer. Though, this should give 
a systematic higher concentration in the second run, but that is not an occasion here. 
 
 
Deviation from single 1        
 AZ1-rat 4 AZ1-rat 5 AZ1-rat 6   AZ2-rat 4 AZ2-rat 5 AZ2-rat 6 
Time(h) Single2 Single2 Single2  Time(h) Single2 Single2 Single2 
15min 0% 7% 18%  15min -12% 0% 4% 
30min 4% 5% 0%  30min -4% 14% 6% 
45min 6% 3% 6%  45min -3% 16% 16% 
1h -9% -1% 5%  1h 7% 0% 0% 
1.5h 2% 5% -6%  1.5h 3% 9% 4% 
2.5h 5% -18% 5%  2.5h 11% 13% -14% 
6h 6% -1% 18%  6h 0% 8% 0% 
24h 0% 0% 0%  24h 0% 0% 0% 
 
 AZ3-rat 4 AZ3-rat 5 AZ3-rat 6 
Time(h) Single2 Single2 Single2 
15min -1% -12% 5% 
30min -7% -1% -8% 
45min -13% 9% -3% 
1h -15% -3% 1% 
1.5h 1% -8% 18% 
2.5h -10% 4% 19% 
6h 7% -9% 0% 
24h 0% 0% 0% 
Table 4.5.4-1 The percentage deviation between the two runs of single AZ 
compounds (AZ1, AZ2 and AZ3) 
 
 






Deviation from pool 1       
 AZ1-rat 4 AZ1-rat 5 AZ1-rat 6   AZ2-rat 4 AZ2-rat 5 AZ2-rat 6 
Time(h) Pool2 Pool2 Pool2  Time(h) Pool2 Pool2 Pool2 
15min 11% 0% -2%  15min 0% 0% -4% 
30min 12% -12% -4%  30min 3% -12% -7% 
45min 15% -4% -11%  45min 14% -4% -5% 
1h 6% 0% -12%  1h -9% 0% -9% 
1.5h -1% 4% -15%  1.5h -13% 4% -6% 
2.5h -13% 4% -23%  2.5h -15% 4% -1% 
6h -11% 9% -20%  6h -10% 9% -2% 
24h 0% 0% 0%  24h 0% 0% 0% 
 
 AZ3-rat 4 AZ3-rat 5 AZ3-rat 6 
Time(h) Pool2 Pool2 Pool2 
15min -4% -5% -4% 
30min 2% -16% -7% 
45min 3% -11% -5% 
1h 12% -2% -9% 
1.5h -13% 7% -6% 
2.5h -18% -2% -1% 
6h -7% -5% -2% 
24h 0% 0% 0% 
Table 4.5.4-2 Percentage deviation between the two runs of pooled AZ compounds 
(AZ1, AZ2 and AZ3) 
 
As for the single samples, the results for the pooled samples were also satisfying with 
a maximum deviation between the two runs at –23 %. An interesting difference from 
the single samples is that the values for the second run of the pooled samples tend to 
be lower than for the first run. This is not comparable with the theory from the single 
samples, that some of the sample could have evaporated when stored in the sample 
organizer. Most likely, the deviations are occasional as they go both ways, and 










4.6 Pharmacokinetic profiles, IV route 
As for the PK profiles of the PO route, plasma samples were spiked with the reference 
compounds corresponding to the concentrations of literature PK values as described in 
methods and experimental. The samples were analysed both in single and 
cassette/pooled mode. 
Seven time points for the literature PK values were chosen, administered via the 
intravenous route (the concentration values for the last time point, 24h were not 
included because of the low concentrations). Standard sample preparation was 
followed, 25µL spiked plasma was precipitated with 150 µL ice cold ACN, 120 µL of 
the supernatant was mixed with 300 µL buffer (mobile phase), before analysis. For 
the pooled samples, 75 µL (25 µL x 3) spiked plasma was precipitated with 200 µL 
ice cold ACN, 120 µL of the supernatant was mixed with 300 µL buffer.  
MS instrumentation used for this experiment was both the UPLC system, and the 1-
column HPLC system, both using acetonitrile gradients. 
 
4.6.1 Single vs. pooled, IV route, results from UPLC 
In table 4.6.1-1 and 4.6.1-2, the results for the PK profiles, IV route analysed on 
UPLC are shown. The figure shows the literature values for seven time points 
together with the measured concentration values for single and pooled samples, and 
















 Diclofenac, conc. [nM]  Deviation from literature Deviation from single 
Time (h) Literature Single Pool  Single Pool  Pool  
0.03 16000 15611 14640  -2% -9%  -7%  
0.1 8000 8465 6948  5% -15%  -22%  
0.3 2500 2706 2687  8% 7%  -1%  
0.6 800 868 879  8% 9%  1%  
1 350 354 356  1% 2%  0%  
3 200 207 254  3% 21%  19%  
6 60 63 49  4% -21%  -27%  
 
 Naproxen, conc. [nM]  Deviation from literature Deviation from single 
Time (h) Literature Single Pool  Single Pool  Pool  
0.03 35000 36197 33502  3% -4%  -8%  
0.1 30000 35870 32324  16% 7%  -11%  
0.3 25000 29658 28606  16% 13%  -4%  
0.6 21000 25382 22468  17% 7%  -13%  
1 20000 22083 20990  9% 5%  -5%  
3 16000 19690 19611  19% 18%  0%  
6 10000 12404 11846  19% 16%  -5%  
 
 Rofecoxib, conc. [nM]  Deviation from literature Deviation from single 
Time (h) Literature Single Pool  Single Pool  Pool  
0.03 5500 5951 5178  8% -6%  -15%  
0.1 4400 4457 4280  1% -3%  -4%  
0.3 2800 3296 2476  15% -13%  -33%  
0.6 1000 1231 991  19% -1%  -24%  
1 500 597 527  16% 5%  -13%  
3 80 46 72  -73% -11%  36%  
6 40 51 NV  22% NV  NV  















 Diazepam, conc. [nM]  Deviation from literature Deviation from single 
Time (h) Literature Single Pool  Single Pool  Pool  
0.03 4200 3996 4922  -5% 15%  19%  
0.1 3700 3408 3568  -9% -4%  4%  
0.3 2500 2252 2564  -11% 2%  12%  
0.6 1500 1318 1490  -14% -1%  12%  
1 1000 918 1129  -9% 11%  19%  
3 250 215 265  -16% 6%  19%  
6 25 23 33  -7% 24%  29%  
 
 Imipramine, conc. [nM]  Deviation from literature Deviation from single 
Time (h) Literature Single Pool  Single Pool  Pool  
0.03 2200 1989 2252  -11% 2%  12%  
0.1 2100 2038 2032  -3% -3%  0%  
0.3 2000 1864 1789  -7% -12%  -4%  
0.6 1900 1755 1519  -8% -25%  -16%  
1 1700 1621 1690  -5% -1%  4%  
3 1000 963 895  -4% -12%  -8%  
6 500 452 395  -11% -27%  -14%  
 
 Propranolol, conc. [nM]  Deviation from literature Deviation from single 
Time (h) Literature Single Pool  Single Pool  Pool  
0.03 10500 9285 9691  -13% -8%  4%  
0.1 8500 7948 7367  -7% -15%  -8%  
0.3 6000 5113 4788  -17% -25%  -7%  
0.6 4500 3862 2605  -17% -73%  -48%  
1 3500 3432 2964  -2% -18%  -16%  
3 1000 935 694  -7% -44%  -35%  
6 250 215 187  -16% -34%  -15%  
Table 4.6.1-2 Results for the basic reference compounds analysed on UPLC 
 
The results from the UPLC analysis are overall quite good with small deviations 
between single and pooled samples. However, there are a few values that exceeds the 
acceptance criterion of ± 25%, but the deviations are not large, and the deviations are 
for single time points and will not affect the whole PK-curve distinctly as shown in 
the following compilation. If we look at the deviation between the single and pooled 
samples for all the reference compounds, only 6 out of 41 values exceeds the 
acceptance criterion. As we will see from the validation experiment later in this study, 
these differences are not related to the LC-technique, but rather to variations in the 





4.6.2 Single vs. pooled, IV route, results from HPLC 
In table 4.6.2-1 and 4.6.2-2, the results for the PK profiles, IV route analysed on 
HPLC are shown. The figure shows the literature values for seven time points 
together with the measured concentration values for single and pooled samples, and 




 Diclofenac, conc. [nM]  Deviation from literature   Deviation from single 
Time (h) Literature Single Pool  Single Pool  Pool  
0.03 16000 16036 15760  0% -2%  -2%  
0.1 8000 7918 7122  -1% -12%  -11%  
0.3 2500 2775 2562  10% 2%  -8%  
0.6 800 838 830  5% 4%  -1%  
1 350 364 347  4% -1%  -5%  
3 200 247 170  19% -18%  -45%  
6 60 70 84  14% 29%  17%  
 
 Naproxen, conc. [nM]  Deviation from literature   Deviation from single 
Time (h) Literature Single Pool  Single Pool  Pool  
0.03 35000 38450 40479  9% 14%  5%  
0.1 30000 34713 34414  14% 13%  -1%  
0.3 25000 25969 30020  4% 17%  13%  
0.6 21000 25502 24189  18% 13%  -5%  
1 20000 22508 22865  11% 13%  2%  
3 16000 19100 20937  16% 24%  9%  
6 10000 12101 13333  17% 25%  9%  
 
 Rofecoxib, conc. [nM]  Deviation from literature   Deviation from single 
Time (h) Literature Single Pool  Single Pool  Pool  
0.03 5500 5416 4751  -2% -16%  -14%  
0.1 4400 4480 4190  2% -5%  -7%  
0.3 2800 2894 2994  3% 6%  3%  
0.6 1000 1066 1209  6% 17%  12%  
1 500 499 591  0% 15%  16%  
3 80 52 63  -54% -27%  17%  
6 40 31 26  -29% -54%  -19%  







 Diazepam, conc. [nM]  Deviation from literature Deviation from single 
Time (h) Literature Single Pool  Single Pool  Pool  
0.03 4200 5932 6435  29% 35%  8%  
0.1 3700 4683 4644  21% 20%  -1%  
0.3 2500 3056 3096  18% 19%  1%  
0.6 1500 1745 1786  14% 16%  2%  
1 1000 1193 1274  16% 22%  6%  
3 250 262 308  4% 19%  15%  
6 25 31 35  20% 28%  9%  
 
 Imipramine, conc. [nM]  Deviation from literature      Deviation from single 
Time (h) Literature Single Pool  Single Pool  Pool  
0.03 2200 1991 1650.3  -10% -33%  -21%  
0.1 2100 1997 1530.4  -5% -37%  -30%  
0.3 2000 1956 1473.6  -2% -36%  -33%  
0.6 1900 1932 1555  2% -22%  -24%  
1 1700 1493 1252.3  -14% -36%  -19%  
3 1000 988 791.7  -1% -26%  -25%  
6 500 498 372.1  0% -34%  -34%  
 
 Propranolol, conc. [nM]  Deviation from literature Deviation from single 
Time (h) Literature Single Pool  Single Pool  Pool  
0.03 10500 8052 9361  -30% -12%  14%  
0.1 8500 5993 6758  -42% -26%  11%  
0.3 6000 4781 4938  -26% -22%  3%  
0.6 4500 3463 4082  -30% -10%  15%  
1 3500 2566 3200  -36% -9%  20%  
3 1000 844 868  -19% -15%  3%  
6 250 207 230  -21% -9%  10%  
Table 4.6.2-2 Results for the basic reference compounds analysed on HPLC 
 
The results from the HPLC analysis are also quite satisfying comparing the 
differences between single and pooled samples. The deviations between single and 
pooled sample are small, and only 4 out of 42 samples exceeds the acceptance 
criterion. As for the UPLC analysis, these deviations must rather be linked to 
variations in the analytical system than to the LC-technique. Comparing the UPLC 
and the HPLC results, they are quite similar, but the advantage using UPLC over 
HPLC is a significant reduction in analysis time. 
 
4.6.3 PK curves, IV route, compilation 
The PK parameters and the PK curves for all the reference compounds are listed in 
table 4.6.3-1 to table 4.6.3-12 and in figure 24 - 29. The figures illustrates the 
estimated IV route for four trials analysed both on UPLC and HPLC in both discrete 
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Figure 24 PK curves for diazepam, IV route 
 
Deviation from Single       
  T1/2 (h) Cmax (nM) Tmax (h) AUClast AUCinf_pred V (L/kg) CL (L/kg) 
Trial 1 0% 8% 0% 6% 6% 6% 6%
Trial 2 4% 23% 0% 18% 18% 12% 16%
Trial 3 1% 30% 0% 26% 26% 20% 21%
Trial 4 4% 12% 0% 0% 0% 4% 0%
Table 4.6.3-2 PK parameters for diazepam, deviation from single, IV route 
 
Diazepam shows small variations between single and pooled samples, the maximum 
deviation for Cmax is 30%. But the most important parameters for the IV route, 
volume of distribution (V) and clearance (CL) show only small deviations. 
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Imipramine: 












































All over, imipramine shows very small variations between single and pooled samples. 
Almost all the PK parameters fulfilled the acceptance criterion, the reason for why the 
deviation for Tmax is so great for trial 1 and 2 is because of the small values, and 
because Tmax is located at the beginning of the PK curve. 
Deviation from Single       
  T1/2 (h) Cmax (nM) Tmax (h) AUClast AUCinf_pred V (L/kg) CL (L/kg) 
Trial 1 12% 17% 70% 13% 17% 7% 21%
Trial 2 12% 11% 70% 4% 8% 4% 9%
Trial 3 10% 3% 0% 9% 12% 3% 14%
Trial 4 5% 3% 0% 16% 17% 15% 21%
Table 4.6.3-4 PK parameters for imipramine, deviation from single, IV route 
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Propranolol: 









































Figure 26 PK curves for propranolol, IV route 
 
 
Deviation from Single       
  T1/2 (h) Cmax (nM) Tmax (h) AUClast AUCinf_pred V (L/kg) CL (L/kg) 
Trial 1 7% 16% 0% 14% 13% 19% 12%
Trial 2 4% 4% 0% 9% 9% 6% 10%
Trial 3 2% 4% 0% 11% 11% 10% 12%
Trial 4 1% 2% 0% 10% 10% 10% 12%
Table 4.6.3-6 PK parameters for propranolol, deviation from single, IV route 
 
 
As shown in the figures for propranolol, there are no large discrepancies between the 











































Figure 27 PK curves for diclofenac, IV route 
 
 
Deviation from Single       
  T1/2 (h) Cmax (nM) Tmax (h) AUClast AUCinf_pred V (L/kg) CL (L/kg) 
Trial 1 19% 2% 0% 7% 5% 26% 6%
Trial 2 18% 4% 0% 7% 6% 25% 6%
Trial 3 26% 6% 0% 4% 5% 21% 5%
Trial 4 2% 22% 0% 20% 20% 28% 25%
Table 4.6.3-8 PK parameters for diclofenac, deviation from single, IV route 
 
 
As illustrated in the PK curves for diclofenac, the deviation between single and 
pooled samples are very small. But still, some of the PK parameters exceed the 




















































The PK curves for naproxen show some more variation between the single and pooled 
samples. But, if we look at the PK parameters, they are all over very satisfying, and in 
analogy to imipramine, the Tmax in the PK curve is completely in the beginning of 
the curve. 
Deviation from Single       
  T1/2 (h) Cmax (nM) Tmax (h) AUClast AUCinf_pred V (L/kg) CL (L/kg) 
Trial 1 22% 5% 0% 7% 21% 2% 14%
Trial 2 2% 14% 0% 13% 12% 12% 7%
Trial 3 9% 7% 0% 4% 1% 7% 7%
Trial 4 13% 6% 70% 1% 7% 7% 7%
Table 4.6.3-10 PK parameters for naproxen, deviation from single, IV route 
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Rofecoxib: 









































Figure 29 PK curves for rofecoxib, IV route 
 
 
Deviation from Single       
  T1/2 (h) Cmax (nM) Tmax (h) AUClast AUCinf_pred V (L/kg) CL (L/kg) 
Trial 1 0% 12% 0% 4% 4% 4% 4%
Trial 2 68% 16% 0% 15% 13% 91% 16%
Trial 3 0% 13% 0% 14% 14% 17% 16%
Trial 4 8% 12% 0% 3% 3% 11% 3%
Table 4.6.3-12 PK parameters for rofecoxib, deviation from single, IV route 
 
 
The PK curves for rofecoxib show very little variation between single and pooled 
samples, but because of the heavy slope in the beginning of the curve, some variations 
can be found for the PK parameters. 
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As shown in the PK curves for the reference compounds, the differences between the 
trials are small, but for imipramine and naproxen, they show some more variation 
with larger scattering between the trials. But, even though there are some variations 
for these compounds, some of the trials still are quite similar both compared with the 
literature values and the difference between single and pooled samples. 
 
4.7 PK curves for reference compounds with formulations 
This was an experiment to investigate the impact of various formulations on the 
spiked PK (PO) curves of the reference compounds. 
 
The formulations used in this experiment were: 
 - Cyclodextrine 
 - Gluconic acid 
 - Meglumine 
 - Dimethyl acetamide (DMA) 
 - Polyethylene glycol 400 (PEG 400) 
 - Hydroxypropyl methyl cellulose (HPMC) + polyoxyethylene    
   sorbitanmonostearate (Tween80®) 
 - Microcrystalline cellulose (MCC)/ Sodium Carboxymethylcellulose   
   (NaCMC) + Lipoid S100®* 
 
*Lipoid S100® is a phospholipid formulation used for drugs with poor water 
solubility for parenteral application. 
 
In the first experiment, both single and pooled spiked PK curves were made. Plasma 
samples were spiked with the reference compounds corresponding to the 
concentrations of literature PK values as done earlier. But, in contrast to the earlier 
experiments where blank plasma was used, now plasma containing formulation was 
used. Blank plasma was spiked with a 5% formulation mixture of cyclodextrine, 
gluconic acid and meglumine. 
 Together with the single PK curves, also pooled PK curves of the three basic and the 
three acidic compounds respectively, were prepared. Also, standard curves without 
formulation were prepared to be able to quantify the results. 
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The samples were analysed on a UPLC-MS system. The same samples were analysed 
twice on order to detect variations in the system. 
There were small variations between the runs, but the results were satisfying for all 
reference compounds, indicating that the formulations (cyclodextrine, gluconic acid 
and meglumine) do not give significant suppression or enhancement. The results for 
naproxen and rofecoxib from the second run are listed in table 4.7-1. The figure 
shows the measured concentration values [nM] for both single and pooled samples, 
together with the literature values. The deviation from the literature values and the 
deviation between single and pooled concentration values are also listed in percentage 
deviation. 
 
Naproxen   Conc. [nM]   Deviation from literature Deviation from single 
Time (h) Literature Single Pool  Single Pool  Pool 
0.25 35000 43045 37298  19% 6%  -15% 
0.5 43000 39450 50614  -9% 15%  22% 
0.75 43000 42607 48632  -1% 12%  12% 
1 43000 43067 50633  0% 15%  15% 
1.5 45000 41925 49737  -7% 10%  16% 
2.5 45000 39640 50685  -14% 11%  22% 
6 40000 39866 44220  0% 10%  10% 
24 3000 3130 3545  4% 15%  12% 
         
         
Rofecoxib   Conc. [nM]   Deviation from literature Deviation from single 
Time (h) Literature Single Pool  Single Pool  Pool 
0.25 70 66 61  -6% -14%  -7% 
0.5 150 141 165  -6% 9%  14% 
0.75 270 252 268  -7% -1%  6% 
1 300 272 310  -10% 3%  12% 
1.5 450 431 435  -5% -3%  1% 
2.5 600 662 560  9% -7%  -18% 
6 450 449 429  0% -5%  -5% 
24 70 65 69  -8% -1%  6% 
Table 4.7-1 Concentrations for naproxen and rofecoxib, including the percentage 
deviation from literature values, and the deviation between single and pooled values 
 
 
In the second experiment, spiked, and then pooled PK curves for both basic and acidic 
compounds were prepared. Totally eight basic pooled PK curves and eight acidic PK 
curves were prepared, and to each curve, a different formulation was added. There 
were totally seven different formulations, and also a curve with blank plasma were 
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analysed as a control. The amount of formulation in the samples was approximately 
5% that were added to blank plasma.  
This experiment was performed on three different LC systems; 
 
 - UPLC, 1-column system, acetonitrile gradient 
 - HPLC, Quattro Ultima, 2-column system, MeOH gradient 
 - HPLC, Quattro Ultima, 1-column system, acetonitrile gradient 
 
In the UPLC system, the results showed some variations, the results for the basic 
compounds for the 1.5 hour time point are listed in table 4.7-2. The figure shows the 
percentage deviation in measured concentrations between the different formulations 
from the blank plasma curve. The results from the other time points can be found in 
Appendix B. 
 
1.5 h Cyclodextrine Gluconic acid Meglumine DMA PEG400 HPMC/Tween 
MCC/NaCMC+ 
Lipoid S100 
Diazepam 3% 6% 14% 5% -13% -1% 21% 
Imipramine 24% 0% 25% 16% -53% -14% 21% 
Propranolol 35% -9% 29% 29% -118% -20% 41% 
Table 4.7-2 Deviation between spiked PK curves with different formulations from the 
spiked PK curve with blank plasma (no formulation), results from UPLC 
 
It is difficult to draw a conclusion from this experiment alone; the deviation depends 
both on formulation and reference compound. However, we can se that PEG 400 
gives a significant suppression, whereas the other formulations do not involve the 
same great impact. 
 
The HPLC systems showed less variation. All over, the acidic reference compounds 
did not seem to be significally affected by any of the formulations even though there 
exist some values that varies more than others. In table 4.7-3, the percentage deviation 
between the different formulations and the curve without formulation are listed for the 
acidic reference compounds. The table shows only the one-hour time point for each 
compound, the other measured time points can be found in Appendix B. These 
samples were analysed on the 2-column HPLC system with a MeOH gradient.  
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1.0 h Cyclodextrine Gluconic acid Meglumine DMA PEG400 HPMC/Tween 
MCC/NaCMC+
Lipoid S100 
Diclofenac 12% 5% 6% 9% 11% 10% 
 
-14% 
Naproxen -1% -11% 21% 16% 0% 22% 
 
8% 
Rofecoxib -21% -2% 7% 3% 16% 5% 
 
-9% 
Table 4.7-3 Percentage deviation between the formulations and the control (blank), 
results from HPLC 
 
For the basic reference compounds (diazepam, imipramine and propranolol), there 
were also some variations, but over all, only PEG 400 seemed to give significant 
suppression. This could be observed for both HPLC analysis systems (1 and 2 
columns). 
 
4.8 Validation experiments 
 The last experiment in this study was a validation experiment, which was necessary 
to be able to evaluate the other results as mentioned in the theory part. The primary 
objective in this experiment was to evaluate the variability in the analytical method. 
 
Standard curves of the six reference compounds were prepared in spiked rat plasma, 
range 10 – 20000 nM. 
Six quality controls (QC) in four concentration levels followed by three blanks were 
prepared, also in spiked rat plasma.  
The concentrations of the controls were: 
 
 - LLQC [25 nM] 
 - LQC [125 nM] 
 - MQC [1250 nM] 
 - HQC [12500 nM] 
 
The reference compounds were divided into two cassette groups of basic (diazepam, 
imipramine and propranolol) and acidic (diclofenac, naproxen and rofecoxib) 
compounds. Standard curves were prepared in both discrete/single and cassette/pooled 
mode. The controls were prepared in cassette mode, and also in discrete mode for the 
compounds diazepam and diclofenac. 
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This resulted in four analysis plates with controls: 
 
 - Basic compounds, cassette mode 
 - Acidic compounds, cassette mode 
 - Diazepam, discrete mode 
 - Diclofenac, discrete mode 
 
The analyze system for this experiment was a UPLC-MS/MS, Waters Acquity 
Quattro Premier XE system, and the experiment were performed at Waters 
corporation in Sollentuna, Sweden in collaboration with AstraZeneca. 
To evaluate the variation over a longer time period, the analysis plates were analysed 
six times subsequent for each plate (Run1 – Run6), and then again one more time 
(Run7) after 24 –72 hours. The pooled, basic compounds were only analysed five 
times subsequently (Run1 – Run5), and then again after 72 hours (Run7). 
The time between the runs for the cassette mode plates were approximately 4 hours 
and 2,5 hours for the discrete mode. 
The acceptance criterion was set to ± 25% from the first run, and not more than 3 out 
of 20 samples could exceed this limit of 25% deviation. 
The deviations from Run1 for all the analytes are listed in Appendix C.  
 
The deviation for the basic compounds (diazepam, imipramine and propranolol) were 
quite satisfying even though some control values falls out of the limit of 25% 
deviation from Run1. This is most apparent for propranolol, but comparing Run1 for 
propranolol, the concentration values seems lower than for all the other runs, and can 
therefore be an explanation to this. This is illustrated in table 4.8-1, showing the 
measured concentration values for the controls of propranolol. The mean values for 










 Literature Run1 Run2 Run3 Run4 Run5 Run7 
LLQC 25 16 22 20 17 21 18 
 25 10 10 10 17 10 10 
 25 9 10 8 13 13 10 
 25 10 12 14 11 11 10 
 25 10 15 13 12 16 10 
 25 12 13 11 11 15 10 
 Mean 11 14 13 13 14 11 
        
LQC 125 68 90 94 89 90 78 
 125 64 104 98 98 104 86 
 125 73 104 108 104 98 91 
 125 73 108 99 97 111 90 
 125 74 103 102 107 95 78 
 125 84 112 115 123 111 99 
 Mean 73 104 103 103 102 87 
        
MQC 1250 662 945 925 909 919 754 
 1250 650 900 876 910 885 730 
 1250 681 978 953 940 942 739 
 1250 770 1120 1047 1047 1075 908 
 1250 892 1286 1236 1321 1246 1125 
 1250 951 1300 1239 1280 1269 1108 
 Mean 768 1088 1046 1068 1056 894 
        
HQC 12500 7657 9209 9264 9247 9031 8141 
 12500 7156 11058 9150 9131 9194 8217 
 12500 7656 9914 9506 9504 9771 8384 
 12500 7702 9726 9844 9669 9678 8942 
 12500 8571 10590 10541 10387 10361 9932 
 12500 10398 12511 12677 12792 12474 12231 
 Mean 8190 10501 10164 10122 10085 9308 
Table 4.8-1 Literature and measured concentration values for propranolol, cassette 
mode 
 
For the acidic compounds (diclofenac, naproxen and rofecoxib), the results are not as 
good as for the basic compounds. Distinctly are the lower concentration values 
remarkably poor. An elucidating reason for this is that the sensitivity in the analysis 
system is poorer for acidic compounds than for basic compounds. That is also the 
reason for why the lowest concentrations in the standard curve are missing (non value, 
NV). This can be illustrated by comparing the chromatograms for both the basic and 
the acidic compounds as shown in figure 30 and 31. 
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LLQC POOL acidic 25 nM 
STD+QC negative
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Figure 30 Chromatograms for the acidic compounds, cassette mode 
 
 
The chromatograms are showing the acidic compounds rofecoxib (top), warfarin (IS), 
diclofenac, naproxen and the TIC (bottom). The response for rofecoxib, diclofenac 
and naproxen are very poor, between 1.73e3 (naproxen) and 5.40e3 (diclofenac), and 
they are below LOQ.  
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LLQC POOL basic 25 nM 
STD+QC positive
Time















































Figure 31 Chromatograms for the basic compounds, cassette mode 
 
 
The chromatograms are showing the basic compounds, warfarin (IS) on the top, 
followed by diazepam, imipramine, propranolol and the TIC chromatogram at the 
bottom. 
Compared to the acidic compounds of the same concentration [25 nM], the response 
is almost up to 100 times better for the basic compounds. The response diversifies 
from 1.09e4 (diazepam) to 1.59e5 (imipramine). The response for warfarin is high in 
both positive and negative mode as expected, because it is the internal standard. It is 
even higher in the negative mode, which also emphasizes that the response for the 
acidic reference compounds is poor. 
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To summarize the results from the validation experiment, the mean concentration 
values [nM] for the controls in each run are listed in table 4.8-2 and 4.8-3.  
 
 
Diazepam (single):       
  Run1 Run2 Run3 Run4 Run5 Run6 Run7 
LLQC 27 27 28 26 27 24 25 
LQC 140 139 146 144 141 139 135 
MQC 1543 1517 1574 1573 1556 1521 1440 
HQC 14769 14463 14638 14430 14531 14482 14684 
        
Diazepam (pool):       
  Run1 Run2 Run3 Run4 Run5 Run7  
LLQC 23 25 26 23 26 23  
LQC 111 115 122 116 120 122  
MQC 1129 1182 1225 1148 1179 1225  
HQC 12300 12678 12581 12484 12545 12969  
        
Imipramine (pool):       
  Run1 Run2 Run3 Run4 Run5 Run7  
LLQC 19 20 20 20 21 25  
LQC 94 112 111 111 111 113  
MQC 925 1098 1081 1098 1057 1065  
HQC 9405 11367 10854 10987 10637 11168  
        
Propranolol (pool):       
  Run1 Run2 Run3 Run4 Run5 Run7  
LLQC 11 14 13 13 14 11  
LQC 73 104 103 103 102 87  
MQC 768 1088 1046 1068 1056 894  
HQC 8190 10501 10164 10122 10085 9308  



















Diclofenac (single):       
  Run1 Run2 Run3 Run4 Run5 Run6 Run7 
LLQC 28 17 23 27 16 27 29 
LQC 149 150 167 153 149 161 160 
MQC 1310 1360 1447 1364 1288 1389 1327 
HQC 13332 14216 14073 14735 14252 14251 14006 
        
Diclofenac (pool):       
  Run1 Run2 Run3 Run4 Run5 Run6 Run7 
LLQC 14 16 15 14 23 12 28 
LQC 115 131 123 115 124 123 105 
MQC 1283 1158 1146 1204 1176 1159 1027 
HQC 14070 12116 14629 14408 13241 13743 14124 
        
Naproxen (pool):       
  Run1 Run2 Run3 Run4 Run5 Run6 Run7 
LLQC 28 69 21 58 81 52 99 
LQC 107 150 147 149 167 140 175 
MQC 1399 1403 1457 1436 1487 1359 1316 
HQC 15776 13552 15698 16270 17251 16029 15424 
        
Rofecoxib (pool):       
  Run1 Run2 Run3 Run4 Run5 Run6 Run7 
LLQC 13 29 NV 16 20 19 18 
LQC 151 151 128 148 148 130 147 
MQC 1591 1571 1663 1575 1396 1452 1537 
HQC 12259 10178 11329 11140 10357 11486 11551 




The percentage difference between the highest and the lowest mean concentration 
values from the quality controls are listed in table 4.8-4 and 4.8-5. 
 
 
  Diazepam(single) Diazepam(pool) Imipramine(pool) Propranolol(pool) 
LLQC 13% 10% 25% 21% 
LQC 8% 9% 17% 30% 
MQC 9% 8% 16% 29% 
HQC 2% 5% 17% 22% 
Table 4.8-4 Percentage difference between highest and lowest mean concentration 





  Diclofenac(single) Diclofenac(pool) Naproxen(pool) Rofecoxib(pool) 
LLQC NV NV NV NV 
LQC 11% 20% 39% 15% 
MQC 11% 20% 11% 16% 
HQC 10% 17% 21% 17% 
Table 4.8-5 Percentage difference between highest and lowest mean concentration 
value of the quality controls, acidic reference compounds 
 
From table 4.8-4 and 4.8-5, we can see that the differences from the basic reference 
compounds are quite small, even though they differ from 2% - 30%. The difference 
tends to be smaller with higher concentrations. This is as expected because of higher 
precision with higher concentrations. This is also the case for the acidic reference 
compounds, and as mentioned earlier, the lowest quality controls (LLQC) are below 
the LOQ for the acidic compounds, and should therefore be excluded. 
 
If we exclude the LLQC for the acidic reference compounds, the results are quite 
good. Out of all the results (Appendix C), only 109 of a total of 1255 results exceed 
the limit of the acceptance criterion ± 25%. The criterion was also that not more than 
3 out of 20 samples should exceed the acceptance criterion. 3 out of 20 correspond to 
15% aberration, whilst 109 of 1255 correspond to 8.7% aberration. 
 
In table 4.8-6 to 4.8-13, the results from this experiment are summarized to show the 
interday accuracy and precision for the reference compounds. 
 
Diazepam(single):    
  LLQC 25nM LQC 125nM MQC 1250nM HQC 12500nM 
mean (n=7) 26.3 140.6 1532 14571 
SD 1.4 3.6 46.5 127.5 
RSD (%) 5.3 2.6 3.0 0.9 
Accuracy(%) 105.2 112.5 122.6 116.6 
Table 4.8-6 Accuracy and precision for diazepam (discrete) 
 
Diazepam(pool):    
  LLQC 25nM LQC 125nM MQC 1250nM HQC 12500nM 
mean (n=6) 24.3 117.7 1181.3 12592.8 
SD 1.5 4.4 39.2 223.1 
RSD (%) 6.2 3.7 3.3 1.8 
Accuracy(%) 97.2 94.2 94.5 100.7 
 Table 4.8-7  Accuracy and precision for diazepam (cassette) 
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Imipramine(pool):    
  LLQC 25nM LQC 125nM MQC 1250nM HQC 12500nM 
mean (n=6) 20.8 108.7 1054 10736.3 
SD 2.1 7.2 65.4 699 
RSD (%) 10.1 6.6 6.2 6.5 
Accuracy(%) 83.2 87 84.3 85.9 
Table 4.8-8  Accuracy and precision for imipramine (cassette) 
 
Propranolol(pool):    
  LLQC 25nM LQC 125nM MQC 1250nM HQC 12500nM 
mean (n=6) 12.7 95.3 986.7 9728.3 
SD 1.4 12.7 127.8 850 
RSD (%) 11 13.3 13 8.7 
Accuracy(%) 50.8 76.2 78.9 77.8 
Table 4.8-9  Accuracy and precision for propranolol (cassette) 
 
Diclofenac(single):    
  LLQC 25nM LQC 125nM MQC 1250nM HQC 12500nM 
mean (n=7) NV 155.6 1355 14123.6 
SD NV 7.1 53.3 419.9 
RSD (%) NV 4.6 3.9 3.0 
Accuracy(%) NV 124.5 108.4 113 
Table 4.8-10  Accuracy and precision for diclofenac (discrete) 
 
Diclofenac(pool):    
  LLQC 25nM LQC 125nM MQC 1250nM HQC 12500nM 
mean (n=7) NV 119.4 1164.7 13761.6 
SD NV 8.4 76.4 854 
RSD (%) NV 7.0 6.6 6.2 
Accuracy(%) NV 95.5 93.2 110.1 
Table 4.8-11  Accuracy and precision for diclofenac (cassette) 
 
Naproxen(pool):    
  LLQC 25nM LQC 125nM MQC 1250nM HQC 12500nM 
mean (n=7) NV 147.9 1408.1 15714.3 
SD NV 21.8 58.3 1120.5 
RSD (%) NV 14.7 4.1 7.1 
Accuracy(%) NV 118.3 112.6 125.7 







Rofecoxib(pool):    
  LLQC 25nM LQC 125nM MQC 1250nM HQC 12500nM 
mean (n=7)    NV 143.3 1540.7 11185.7 
SD NV 9.9 89.8 718.8 
RSD (%) NV 6.9 5.8 6.4 
Accuracy(%) NV 114.6 123.3 89.5 
Table 4.8-13  Accuracy and precision for rofecoxib (cassette) 
 
As expected, the precision (RSD) tends to be better with higher concentrations 
because of smaller relative variations for all compounds. As we have seen earlier in 
this experiment, there are small variations between runs, but some compounds have a 
greater variation from the theoretical values (Accuracy). Although, the accuracy falls 
within the ±25% acceptance criterion for most of the controls. 
 
This experiment indicates that there are some variations in the analytical method even 
though the variations are quite even. The dispersion between runs of the same samples 
shows some variation, but overall, they falls within a limit of  ± 25%. This implies 
that even though not all the results in this whole study fulfilled the ± 25% acceptance 
criterion, this difference is not related to the LC-technique, but rather to the variability 







































The results from this study indicate that cassette analysis can be used. Examining 
differences between six reference compounds analysed in discrete/single and 
cassette/pooled mode ratifies this. Results from the in vivo studies with in house 
AstraZeneca compounds, and the results from the validation experiment substantiate 
the assumptions. A general ± 25% acceptance criterion was set for deviations between 
single and pooled samples. When spiking PK (IV) profiles with the reference 
compounds to be analysed on HPLC, only 4 out of 42 samples exceeded the 
acceptance criterion. A comparison of single and pooled standard curves for the AZ 
compounds showed small variations, the deviations varied from –6% to 13%. 
 
This assessment indicates that there are no large discrepancies between samples 
analysed in discrete or cassette mode. There are no large discrepancies between the 
analytical results from UPLC and HPLC either. By the use of cassette analysis instead 
of discrete analysis, the throughput increases considerably. The throughput increases 
additionally with use of cassette analysis in combination with UPLC-MS/MS instead 
of HPLC-MS/MS, and can then increase the throughput at least five times. Because of 
the increased throughput, there will also be massive savings in time for analysis and 
costs connected to this. 
 
However, there are some variations in the analysis that not fulfilled the ± 25% 
acceptance criterion. This difference is on the other hand not related to the LC-
technique, but rather to variability in the analytical method , scattering in the analysis 
system, and variations in the sample preparation. The basis for this assumption can be 
found in the validation experiment, which also have the same variations. Thereby, 
there can always be some variations in the analysis, regardless of the samples are 
single or pooled. 
 
Because of additional dilution in the sample preparation step for the pooled samples, 
there is a small loss of sensitivity compared with the single samples. However, the 
additional dilution is only 1.6 times higher for the pooled samples, and is therefore 
only of concern when working with very small concentrations. 
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Some formulations can give ion suppression or ion enhancement, for instance PEG 
400. When using formulations where the impact on the analytes is unknown, an ion 
suppression check should be performed. Also, before pooling of unknown 
compounds, a check of how the compounds affects each other compared to single 
analysis should be performed. Even though there are more issues to consider when 
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4.3.1 Reducing the amount of acetonitrile used for protein precipitation 
 
Measured area and concentration for the reference compounds with and without 
formulation (F). Adding different amounts of ACN in the sample preparation, 4.25 
minute method: 
 
Diazepam, 450 µL ACN   Diazepam, 300 µL ACN  
Area F_Area Conc. F_Conc.  Area F_Area Conc. F_Conc. 
356 483 5 5  569 522 5 5 
707 752 10 9  1183 1013 11 10 
2451 2125 33 29  3376 2815 34 30 
8318 7889 113 114  11371 10411 116 113 
28923 27065 393 397  36000 34328 373 377 
90270 89858 1249 1338  112063 120583 1192 1353 
221414 225405 3199 3447  275623 284207 3109 3336 
593258 586286 10171 9727  718650 712598 10565 9828 
 
Diazepam, 200 µL ACN  
Area F_Area Conc. F_Conc. 
591 596 5 5 
1237 1092 10 10 
4041 3487 34 31 
13259 13158 113 116 
45514 44735 392 397 
134525 139757 1192 1269 
324390 350967 3084 3363 





Imipramine, 450 µL ACN   Imipramine, 300 µL ACN  
Area F_Area Conc. F_Conc.  Area F_Area Conc. F_Conc. 
542 827 5 15  1131 680 5 5 
793 571 9 10  1798 987 11 9 
2409 1728 33 31  4109 2549 30 30 
7824 5616 113 100  14801 8788 121 114 
27268 22247 401 393  47716 28260 401 375 
87079 74061 1298 1265  138823 99914 1195 1346 
210520 237545 3197 3710  351309 260885 3163 3587 




Imipramine, 200 µL ACN  
Area F_Area Conc. F_Conc. 
496 560 5 5 
1025 1175 10 10 
3287 3050 33 27 
11054 12515 113 111 
36631 46029 376 407 
120469 142508 1258 1263 
299087 413732 3259 3682 




Propranolol, 450 µL ACN   Propranolol, 300 µL ACN  
Area F_Area Conc. F_Conc.  Area F_Area Conc. F_Conc. 
763 1004 5 6  1044 907 5 5 
1161 1210 9 8  1803 1527 11 10 
3342 3141 31 29  4722 4243 32 30 
11792 11091 114 114  16062 15252 118 114 
41770 38101 410 406  52610 49386 395 375 
129456 127041 1297 1376  149523 173350 1151 1353 
316659 329457 3300 3636  391393 416485 3193 3425 
829417 821774 9923 9491  1013540 988082 10392 9678 
 
Propranolol, 200 µL ACN  
Area F_Area Conc. F_Conc. 
807 958 5 5 
1470 1739 9 10 
4911 5048 31 30 
17776 18805 114 115 
62857 65636 408 406 
190066 194951 1268 1237 
449662 499545 3209 3384 




Diclofenac, 450 µL ACN   Diclofenac, 300 µL ACN  
Area F_Area Conc. F_Conc.  Area F_Area Conc. F_Conc. 
25 NV 5 NV  87 101 NV NV 
61 NV 11 NV  260 213 10 10 
156 154 26 34  495 431 30 31 
820 240 137 46  1379 1237 115 107 
1671 2784 272 366  4114 3877 370 382 
8805 9004 1479 1154  13803 13128 1285 1330 
22598 29387 3573 3740  42128 35121 3548 3446 
56516 81307 9662 9731  101248 94407 9765 9832 
 
 95 
Diclofenac, 200 µL ACN  
Area F_Area Conc. F_Conc. 
168 89 5 5 
296 187 12 10 
666 634 31 35 
1734 2148 93 118 
7136 5975 458 351 
19557 20715 1183 1256 
49638 47725 3255 3188 




Naproxen, 450 µL ACN   Naproxen, 300 µL ACN  
Area F_Area Conc. F_Conc.  Area F_Area Conc. F_Conc. 
NV NV NV NV  NV 48 NV 10 
NV NV NV NV  53 126 10 34 
48 25 34 34  150 129 40 34 
172 38 121 42  325 367 104 107 
413 622 284 362  1080 1176 364 376 
2003 2083 1418 1156  3587 4062 1230 1307 
5319 7019 3511 3754  10558 10847 3220 3295 
14111 20471 9779 9742  30563 33505 10128 9992 
 
Naproxen, 200 µL ACN  
Area F_Area Conc. F_Conc. 
49 118 NV 20 
146 60 10 10 
290 203 33 38 
657 610 97 119 
2178 1635 406 342 
7271 5645 1275 1202 
19940 14338 3608 3235 




Rofecoxib, 450 µL ACN   Rofecoxib, 300 µL ACN  
Area F_Area Conc. F_Conc.  Area F_Area Conc. F_Conc. 
NV NV NV NV  NV 22 NV NV 
NV NV NV NV  NV 86 NV 10 
45 18 34 34  118 141 35 30 
188 43 119 49  299 355 94 105 
486 652 291 368  1278 1112 398 399 
2261 2127 1391 1152  4199 3449 1329 1310 
6121 6865 3618 3749  11595 9248 3372 3522 
14160 18052 9646 9702  27645 22053 9858 9723 
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Rofecoxib, 200 µL ACN  
Area F_Area Conc. F_Conc. 
26 64 5 15 
43 45 9 10 
173 113 39 31 
453 474 111 142 
1363 1191 384 387 
4180 3187 1102 1084 
11506 7092 3269 2721 
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Measured area and concentration for the reference compounds with and without 
formulation (F). Adding different amounts of ACN in the sample preparation, 7.5 
minute method: 
 
Diazepam, 450 µL ACN   Diazepam, 300 µL ACN  
Area F_Area Conc. F_Conc.  Area F_Area Conc. F_Conc. 
687 556 5 5  589 738 5 5 
1040 864 9 9  1169 1423 10 10 
3522 2727 34 31  3372 4178 31 31 
11206 9727 112 112  12149 15179 113 113 
38798 34547 396 403  40754 49415 383 372 
122915 112727 1279 1332  135498 178675 1287 1380 
297437 278752 3221 3376  342223 399986 3330 3227 
798803 748783 10082 9815  942078 1032575 9949 9950 
 
Diazepam, 200 µL ACN  
Area F_Area Conc. F_Conc. 
1193 1123 5 5 
1714 1942 9 9 
5351 6294 34 32 
16859 22617 115 118 
57501 71381 403 378 
169316 234397 1215 1277 
419358 563060 3148 3261 





Imipramine, 450 µL ACN   Imipramine, 300 µL ACN  
Area F_Area Conc. F_Conc.  Area F_Area Conc. F_Conc. 
361 526 5 5  130 696 5 5 
620 1002 9 11  320 1354 10 10 
1920 2476 29 28  1033 4508 29 31 
6740 8226 100 95  4207 15308 112 106 
27312 36288 402 421  14982 53535 393 368 
100108 124457 1418 1418  51090 209830 1318 1434 
277517 314705 3638 3458  138813 508302 3463 3440 
887176 986637 9669 9751  431622 1484713 9827 9744 
 
Imipramine, 200 µL ACN  
Area F_Area Conc. F_Conc. 
405 1172 6 5 
508 2040 8 9 
1492 6493 33 31 
4907 23665 117 113 
15641 78207 382 373 
52596 291046 1277 1390 
152039 714669 3565 3416 





Propranolol, 450 µL ACN   Propranolol, 300 µL ACN  
Area F_Area Conc. F_Conc.  Area F_Area Conc. F_Conc. 
927 762 5 5  761 1023 5 5 
1430 1245 9 10  1280 1777 9 10 
4274 3377 33 31  4079 5170 31 31 
13791 10720 111 105  14726 18600 112 114 
48849 37225 400 371  53260 61087 409 380 
153568 139704 1286 1404  167540 213732 1304 1364 
376608 347018 3289 3519  415828 487803 3340 3265 
983713 929943 9971 9656  1105752 1227900 9876 9901 
 
Propranolol, 200 µL ACN  
Area F_Area Conc. F_Conc. 
1385 1461 5 5 
2328 2358 10 9 
6941 7878 32 33 
23608 27227 112 116 
83923 87935 406 382 
253683 288021 1262 1290 
612665 685577 3237 3290 




Diclofenac, 450 µL ACN   Diclofenac, 300 µL ACN  
Area F_Area Conc. F_Conc.  Area F_Area Conc. F_Conc. 
24 0 0 0  167 194 5 4 
95 340 10 32  271 291 12 13 
249 356 35 34  677 652 37 39 
657 418 101 42  1593 1353 97 95 
1843 2835 295 361  5107 4550 324 353 
9593 8491 1496 1154  20007 16132 1358 1230 
24459 28042 3695 3784  46188 40592 3423 3165 
70560 76273 9599 9709  112128 109962 9823 10292 
 
Diclofenac, 200 µL ACN  
Area F_Area Conc. F_Conc. 
251 250 5 4 
382 566 11 15 
841 1031 33 33 
2078 3466 93 120 
9437 8268 452 295 
22589 31096 1132 1200 
60905 70669 3384 2963 





Naproxen, 450 µL ACN   Naproxen, 300 µL ACN  
Area F_Area Conc. F_Conc.  Area F_Area Conc. F_Conc. 
12 0 0 0  81 31 16 5 
33 46 10 38  62 39 10 9 
62 40 38 34  121 103 31 37 
144 65 114 53  345 243 116 103 
285 512 249 381  998 836 354 383 
1583 1505 1403 1139  3422 2956 1266 1285 
4541 5049 3791 3599  9831 7822 3642 3253 
13608 16243 9646 9874  28397 25390 9761 10038 
 
Naproxen, 200 µL ACN  
Area F_Area Conc. F_Conc. 
53 37 0 4 
142 88 11 15 
173 168 19 34 
509 575 98 120 
2122 1337 471 284 
5922 5312 1352 1180 
16576 14528 3788 3272 




Rofecoxib, 450 µL ACN   Rofecoxib, 300 µL ACN  
Area F_Area Conc. F_Conc.  Area F_Area Conc. F_Conc. 
26 0 11 0  38 39 5 5 
26 27 10 11  51 45 11 9 
56 47 35 25  88 95 23 30 
158 71 121 42  339 282 115 115 
307 608 249 410  1137 911 400 406 
1781 1735 1447 1227  3761 3066 1392 1324 
4634 5452 3662 3802  9287 8011 3621 3442 
13577 14706 9678 9611  23334 21219 9562 9785 
 
Rofecoxib, 200 µL ACN  
Area F_Area Conc. F_Conc. 
51 31 5 5 
64 65 9 12 
165 168 32 36 
524 551 118 118 
1752 1730 411 378 
4846 4711 1191 1100 
12688 10909 3440 2759 
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4.7 PK curves for reference substances with formulations 
 
Deviations between spiked PK curves with different formulations from the spiked PK 













Concentrations for diclofenac, naproxen and rofecoxib, including the percentage 
deviation between the formulations and the control (blank), results from HPLC: 
 
Diclofenac Conc. [nM]       
Time (h) Blank Cyclodextrine Gluconic acid Meglumine DMA PEG 400 HPMC/Tween 
MCC/NaCMC+ 
Lipiod S100 
0.5 1638 1261 1565 1506 1437 1636 1526 1549 
0.75 1169 1106 1095 1209 1211 1297 1228 952 
1 774 875 816 821 847 865 864 678 
         
Deviation from blank plasma      
Time (h) Blank Cyclodextrine Gluconic acid Meglumine DMA PEG 400 HPMC/Tween 
MCC/NaCMC+ 
Lipiod S100 
0.5   -30% -5% -9% -14% 0% -7% -6% 
0.75   -6% -7% 3% 3% 10% 5% -23% 
1   12% 5% 6% 9% 11% 10% -14% 
         
         
Naproxen Conc. [nM]       
Time (h) Blank Cyclodextrine Gluconic acid Meglumine DMA PEG 400 HPMC/Tween 
MCC/NaCMC+ 
Lipiod S100 
0.5 4354 3914 3383 4635 3859 4799 4062 5005 
0.75 4560 3955 3656 5363 4346 4668 5224 4742 
1 4172 4126 3745 5293 4956 4180 5320 4524 
         
Deviation from blank plasma      
Time (h) Blank Cyclodextrine Gluconic acid Meglumine DMA PEG 400 HPMC/Tween 
MCC/NaCMC+ 
Lipiod S100 
0.5   -11% -29% 6% -13% 9% -7% 13% 
0.75   -15% -25% 15% -5% 2% 13% 4% 
1   -1% -11% 21% 16% 0% 22% 8% 
         
         
Rofecoxib Conc. [nM]       
Time (h) Blank Cyclodextrine Gluconic acid Meglumine DMA PEG 400 HPMC/Tween 
MCC/NaCMC+ 
Lipiod S100 
0.5 210 129 167 156 161 211 197 151 
0.75 189 157 160 195 219 259 255 193 
1 246 203 241 264 254 294 258 225 
         
Deviation from blank plasma      
Time (h) Blank Cyclodextrine Gluconic acid Meglumine DMA PEG 400 HPMC/Tween 
MCC/NaCMC+Lipiod 
S100 
0.5   -63% -26% -35% -31% 0% -7% -39% 
0.75   -21% -18% 3% 14% 27% 26% 2% 





4.8 Validation experiments 
 
Percentage deviation from Run1 for diazepam, both single and pooled: 
 DIAZEPAM, SINGLE    DIAZEPAM, POOLED  
 Run2 Run3 Run4 Run5 Run6 Run7  Run2 Run3 Run4 Run5 Run7 
STD -1% 2% -1% 1% -2% -2%  -1% 6% 1% 0% 3% 
 2% -8% 4% -3% 5% 7%  3% -22% -5% 1% -9% 
 0% -2% -4% -2% 1% -1%  -1% 1% 2% -3% -4% 
 0% 3% -1% 1% -3% 0%  0% 6% 1% -1% 4% 
 -1% 2% 1% 1% 0% -2%  -3% 0% -2% 2% 2% 
 -1% 1% 1% 2% -1% -3%  2% 6% 1% 0% 2% 
 0% 1% 0% 0% -1% -1%  -1% 4% 3% 3% 4% 
 0% -1% 0% 0% 1% 2%  0% -4% -2% -2% -3% 
             
LLQC -3% 2% -10% 1% -12% -12%  -9% 0% 15% -5% -23% 
 0% 1% -3% -16% -8% -10%  13% 1% -6% 22% 0% 
 6% 4% -7% -1% -7% -13%  16% 16% 4% -2% -6% 
 -12% 0% -9% -2% -25% -18%  -4% 7% 3% 2% 4% 
 6% 0% 2% 5% -7% -3%  12% 14% -7% 16% 18% 
 -2% 6% -4% -6% -17% -1%  -1% 18% -26% 22% 10% 
             
LQC 1% 3% 3% -2% -2% -5%  6% 12% 3% 9% 12% 
 1% 5% 4% 3% 0% -2%  9% 13% 12% 13% 18% 
 -1% 10% 7% 4% 6% -2%  -1% 3% 3% 2% 1% 
 -3% 3% 1% 2% -3% -5%  6% 13% -1% 10% 15% 
 0% 5% 2% -2% -1% 1%  5% 6% 7% 3% 4% 
 0% 1% 0% -1% -4% -6%  -2% 7% 2% 10% 1% 
             
MQC -4% 2% 9% 0% -2% -5%  5% 11% 5% 4% 11% 
 0% 3% -1% -1% -3% -6%  3% 8% 2% 3% 6% 
 -3% 1% 0% 0% -3% -12%  2% 6% -1% 3% 5% 
 -2% 1% -1% 0% -1% -4%  4% 9% 0% 5% 8% 
 -1% 3% 3% 4% -1% -7%  8% 10% 1% 5% 9% 
 -1% 2% 1% 3% 2% -10%  5% 5% 3% 5% 8% 
             
HQC -3% -4% -6% -4% -4% -3%  -2% 3% 2% -1% 5% 
 -1% -1% -2% -2% -3% -3%  12% 3% 2% 3% 8% 
 -2% -2% -3% -3% -2% -6%  5% 3% 3% 4% 2% 
 -3% -4% -2% 0% -3% 5%  1% 3% 1% 3% 7% 
 -2% 3% -2% 1% 1% 11%  -1% 1% -1% 2% 3% 






Percentage deviation from Run1 for imipramine and propranolol, pooled: 
 IMIPRAMINE, POOLED   PROPRANOLOL, POOLED 
 Run2 Run3 Run4 Run5 Run7  Run2 Run3 Run4 Run5 Run7 
STD 2% 3% 2% 0% 1%  7% 5% 5% 6% 3% 
 -7% -10% -8% 1% -5%  -22% -13% -15% -20% -8% 
 -2% -3% -4% -5% -5%  -8% -15% -10% -9% -3% 
 3% 3% 2% 0% 4%  1% 1% -1% -1% 2% 
 0% 3% 1% 1% 1%  10% 12% 10% 12% 6% 
 6% 5% 7% 3% 2%  14% 12% 13% 12% 2% 
 5% 6% 8% 5% 6%  10% 11% 12% 12% 6% 
            
LLQC 0% 6% -1% 10% 12%  28% 17% 6% 21% 8% 
 8% 5% 7% 5% 20%  2% -3% 40% -1% -1% 
 10% 3% 10% 16% 24%  6% -13% 26% 30% 3% 
 6% 5% 8% 12% 32%  11% 28% 3% 6% -9% 
 10% 10% 15% 13% 30%  30% 22% 14% 35% 2% 
 14% 12% 10% 17% 30%  9% -10% -10% 19% -22% 
            
LQC 11% 11% 11% 12% 16%  24% 27% 23% 24% 12% 
 15% 16% 15% 17% 19%  38% 34% 34% 38% 25% 
 14% 13% 13% 11% 14%  30% 33% 30% 26% 20% 
 18% 14% 14% 13% 17%  32% 25% 25% 34% 19% 
 18% 16% 19% 18% 16%  28% 27% 31% 23% 5% 
 20% 21% 22% 20% 23%  25% 27% 32% 24% 15% 
            
MQC 16% 16% 16% 12% 12%  30% 28% 27% 28% 12% 
 15% 14% 16% 11% 12%  28% 26% 29% 26% 11% 
 16% 16% 15% 13% 10%  30% 29% 28% 28% 8% 
 14% 13% 12% 12% 10%  31% 26% 26% 28% 15% 
 18% 15% 21% 13% 18%  31% 28% 32% 28% 21% 
 15% 13% 14% 13% 16%  27% 23% 26% 25% 14% 
            
HQC 11% 14% 12% 10% 12%  17% 17% 17% 15% 6% 
 35% 15% 19% 14% 20%  35% 22% 22% 22% 13% 
 17% 15% 15% 15% 13%  23% 19% 19% 22% 9% 
 10% 13% 13% 9% 15%  21% 22% 20% 20% 14% 
 13% 11% 15% 10% 19%  19% 19% 17% 17% 14% 










Percentage deviation from Run1 for diclofenac, both single and pooled: 
 DICLOFENAC, SINGLE    DICLOFENAC, POOLED   
 Run2 Run3 Run4 Run5 Run6 Run7  Run2 Run3 Run4 Run5 Run6 Run7 
STD -1% 7% -3% -1% -2% -3%  NV NV NV NV NV NV 
 6% -37% 12% 7% 10% 12%  -5% -1% 3% 2% 4% 7% 
 -6% 5% 2% -10% -2% -5%  12% 4% -15% -8% -24% -48% 
 -4% 1% -13% -3% -7% -5%  17% -2% -3% 1% 2% 8% 
 -2% 4% 1% -3% 0% -5%  -9% -1% 5% 3% 7% 16% 
 NV NV NV NV NV NV  -10% 4% 8% 1% 4% -3% 
 1% 3% 1% 3% 2% 4%  -17% -5% -4% 1% 0% -2% 
 -2% -4% 0% -3% -1% -3%  9% 1% -1% -3% -3% -6% 
              
LLQC -82% 1% -3% -39% -45% -6%  -250% 37% 3% 28% -48% 37% 
 -10% -5% -13% -13% -22% 12%  64% -267% 47% 85% 63% 64% 
 -39% -43% 19% -230% 21% 11%  -10% 70% 62% 71% 64% 81% 
 -20% -11% 5% -156% 36% 18%  -79% -56% -135% -151% -495% 15% 
 -60% -46% 7% -76% 0% -27%  28% -17% 6% 13% -110% 58% 
 -421% -38% -46% -104% -33% 1%  49% -37% -65% 43% 0% 41% 
              
LQC 14% 27% 21% 21% 26% 20%  0% -21% -56% -13% -2% -40% 
 10% 2% -9% 0% 4% -5%  13% 13% 19% -7% 23% -7% 
 1% 11% 5% -4% 3% 12%  13% 10% -5% 15% -1% 12% 
 1% 11% 0% -24% -2% -1%  21% -12% 10% -1% 5% 1% 
 -2% 7% -13% 4% 5% 14%  0% 23% 3% 11% -11% -20% 
 -33% 2% 2% -3% 6% -2%  26% 14% 6% 29% 18% -18% 
              
MQC -1% 4% 2% -7% 0% 2%  -10% -17% -12% -20% -24% -34% 
 5% 10% 2% -3% 6% 3%  -11% -7% -7% 1% -11% -30% 
 -2% 5% 3% -7% 3% -2%  -10% -14% -8% -10% -10% -36% 
 8% 17% 9% 0% 8% 0%  -10% -12% -2% -10% -8% -27% 
 7% 13% 5% 6% 10% 4%  -12% -14% -6% -9% -7% -10% 
 4% 7% 3% -2% 6% 2%  -12% -9% -5% -9% -7% -16% 
              
HQC 3% 2% 0% 4% 3% -3%  -18% -6% -1% -21% -7% -20% 
 7% 7% 4% 7% 7% 5%  -8% 7% 0% -6% -8% -17% 
 8% 6% 6% 6% 11% 10%  -18% 10% 2% -12% 0% 21% 
 6% 6% 7% 8% 3% 11%  -16% -2% 4% 4% 4% -12% 
 7% 6% 3% 7% 7% 2%  -21% 5% 2% 1% -3% 5% 










Percentage deviation from Run1 for naproxen and rofecoxib, pooled: 
 NAPROXEN, POOLED    ROFECOXIB, POOLED   
 Run2 Run3 Run4 Run5 Run6 Run7  Run2 Run3 Run4 Run5 Run6 Run7 
STD NV NV NV NV NV NV  NV NV NV NV NV NV 
 NV NV NV NV NV NV  -3% NV 4% -5% -8% 7% 
 -8% -31% -4% 0% -5% -4%  4% -19% -19% 11% 19% -28% 
 27% -1% 16% 0% 19% 14%  9% 10% 18% 0% -8% 0% 
 -7% 3% -7% 4% -6% 1%  -1% -4% -3% -1% -10% 20% 
 -10% 12% -4% -4% -8% -10%  -6% 10% 1% -11% -4% -5% 
 -12% 3% -2% -2% -3% -3%  -13% 0% -8% -8% -4% -3% 
 6% -3% 1% 1% 2% 2%  5% -2% 3% 10% 5% 0% 
              
LLQC 61% -71% 47% 58% 49% 71%  65% NV 50% 77% 70% 47% 
 54% -224% 63% 69% 37% 74%  52% NV -98% 3% -32% -4% 
 78% -89% 63% 78% 65% 80%  66% NV -14% 33% 68% 24% 
 36% -7% 15% 35% 26% 49%  68% NV 33% 53% 15% 72% 
 35% -183% 28% 56% 22% 64%  51% NV 55% 1% 28% -202% 
 84% 74% 84% 89% 79% 89%  25% NV -3% 17% -8% -2% 
              
LQC 28% 17% -5% 25% 15% 29%  24% 9% 20% 5% 36% 5% 
 34% 50% 48% 33% 44% 62%  -3% -5% -1% -30% -22% 2% 
 30% 38% 41% 28% 3% 43%  10% -18% -1% 9% -41% -3% 
 52% 48% 53% 47% 25% 52%  11% -44% 14% 4% 2% 8% 
 30% 52% 48% 49% 63% 43%  -40% -57% -30% -3% -73% -33% 
 2% -108% -50% 35% -44% 5%  -7% -4% -18% -4% -46% 4% 
              
MQC -2% -4% -5% -5% -8% -8%  -3% 3% 1% -19% -19% 5% 
 -3% -2% -18% 5% 10% -19%  -2% 11% 9% 1% -1% -4% 
 -2% 17% 11% 9% 9% -14%  -9% -11% -20% -27% -20% -9% 
 5% 4% 15% 12% 0% 1%  5% 6% 1% -16% -5% -4% 
 -2% -4% 10% 6% -10% 3%  0% 6% 0% -13% -8% -8% 
 6% 9% -3% 8% -24% -4%  0% 9% 3% -12% -6% 0% 
              
HQC -10% -3% 6% -7% 3% -3%  -18% -9% -9% -19% 0% 3% 
 -20% 1% 3% -1% -4% -1%  -24% -7% -13% -28% -11% 2% 
 -10% -1% -2% 11% 6% 0%  -17% -5% -10% -17% -8% -17% 
 -18% -9% -2% 15% -1% -4%  -14% -6% -1% -9% 1% 3% 
 -27% 6% 7% 24% 3% 0%  -24% -12% -14% -15% -13% -22% 
 -16% 1% 6% 3% 1% -6%  -26% -11% -14% -20% -13% -17% 
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